[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fDK_nll6TqpMRZiNjjxdEhWoxX03qLdZ12m13VFRMKHM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"National Institute of Neurological Disorders and Stroke (NINDS)",[4],599,false,58,17,108585,453,[13,16,19,22,25,27,30,33],{"name":14,"count":15},"Healthy",93,{"name":17,"count":18},"Parkinson Disease",33,{"name":20,"count":21},"Epilepsy",31,{"name":23,"count":24},"Stroke",27,{"name":26,"count":24},"Multiple Sclerosis",{"name":28,"count":29},"Parkinson's Disease",26,{"name":31,"count":32},"Cerebrovascular Accident",25,{"name":34,"count":35},"Focal Dystonia",21,[37,42,47,52,57,62,67,72,77,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT02531880","Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy","2026-07-01","Mangafodipir",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT02522611","Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain","2026-12-01","Resiniferatoxin",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05350774","Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2","2026-12-15","IV normal saline",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT07204977","Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)","2027-09-30","Acamprosate calcium",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT04799288","Teriflunomide in HTLV-1 Associated Myelopathy\u002FTropical Spastic Paraparesis","2027-12-31","Teriflunomide",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT07388550","Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)","2028-01-01","Keytruda",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT04569591","DDAVP for Pituitary Adenoma","2028-02-26","Desmopressin acetate",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT02784210","Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques","2028-12-31","Methylprednisolone",{"nctId":78,"briefTitle":79,"date":75,"intervention":80},"NCT03648905","Clinical Laboratory Evaluation of Chronic Autonomic Failure","13N-Ammonia",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT07511049","Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study","2029-12-31","Brincidofovir",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,132,150,172,212,232,257,275,295,323,346,366,391,428,450,468,486,504,554,602,634,652,675,713,737,755,781,799,817,841,859,882,906,931,954,979,997,1015,1077,1125,1166,1210,1249,1277,1308,1330,1363,1397,1429,1455,1480,1505,1523,1541,1565,1588,1606,1631,1649,1673,1698,1721,1746,1771,1789,1813,1838,1861,1879,1902,1925,1947,1969,1992,2013,2031,2054,2078,2100,2118,2143,2168,2192,2218,2242,2266,2290,2308,2326,2351,2374,2397,2424,2447,2473,2491,2515,2539,2565,2588,2606,2634,2658,2682,2705,2728,2746,2768,2786,2804,2835,2858,2876,2901,2924,2949,2974,2997,3021,3046,3070,3098,3116,3134,3152,3174,3199,3217,3241,3265,3289,3312,3335,3358,3381,3405,3428,3451,3475,3498,3523,3555,3585,3621,3644,3668,3690,3715,3733,3754,3772],{"intervention":76,"totalTrials":95,"cells":96},2,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":113,"PHASE4":128,"NA":130},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":112,"soonestReadout":75},[104],{"nctId":73,"briefTitle":74,"status":105,"phases":106,"primaryCompletion":75,"completion":75,"start":107,"enrollment":108,"conditions":109,"interventions":110},"RECRUITING",[89],"2016-10-05",30,[26],[76,111],"Prednisone",1,{"trials":114,"activeCount":99},[115],{"nctId":116,"briefTitle":117,"status":118,"phases":119,"primaryCompletion":120,"start":121,"enrollment":122,"conditions":123,"interventions":125},"NCT00004759","Methylprednisolone Given by 24-Hour or 48-Hour Infusion Versus Tirilazad for Acute Spinal Cord Injury","COMPLETED",[90],"2007-08","1991-12",497,[124],"Spinal Cord Injury",[126,127],"methylprednisolone","tirilazad",{"trials":129,"activeCount":99},[],{"trials":131,"activeCount":99},[],{"intervention":111,"totalTrials":112,"cells":133},{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":144,"PHASE4":146,"NA":148},{"trials":135,"activeCount":99},[],{"trials":137,"activeCount":99},[],{"trials":139,"activeCount":112,"soonestReadout":75},[140],{"nctId":73,"briefTitle":74,"status":105,"phases":141,"primaryCompletion":75,"completion":75,"start":107,"enrollment":108,"conditions":142,"interventions":143},[89],[26],[76,111],{"trials":145,"activeCount":99},[],{"trials":147,"activeCount":99},[],{"trials":149,"activeCount":99},[],{"intervention":46,"totalTrials":112,"cells":151},{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":166,"PHASE4":168,"NA":170},{"trials":153,"activeCount":99},[],{"trials":155,"activeCount":99},[],{"trials":157,"activeCount":112,"soonestReadout":45},[158],{"nctId":43,"briefTitle":44,"status":159,"phases":160,"primaryCompletion":45,"completion":45,"start":161,"enrollment":108,"conditions":162,"interventions":165},"NOT_YET_RECRUITING",[88,89],"2026-06-27",[163,164],"Intractable Pain","Palliative Care",[46],{"trials":167,"activeCount":99},[],{"trials":169,"activeCount":99},[],{"trials":171,"activeCount":99},[],{"intervention":173,"totalTrials":112,"cells":174},"LMP744",{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":206,"PHASE4":208,"NA":210},{"trials":176,"activeCount":99},[],{"trials":178,"activeCount":99},[],{"trials":180,"activeCount":112,"soonestReadout":185},[181],{"nctId":182,"briefTitle":183,"status":105,"phases":184,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":205},"NCT07416188","Novel Indenoisoquinolone CMYC\u002FTOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma",[88,89],"2030-12-31","2032-12-31","2026-06-07",40,[190,191,192,193,194,195,196,197,198,199,200,201,202,203,204],"Recurrent Glioblastoma","Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype","Relapsed Cancer","Recurrent Tumor","Glioblastoma Multiforme","Recurring Glioblastoma","Brain and Central Nervous System Tumors","Glioma","Glioblastomas","Grade IV Astrocytoma","GBM","Recurrent Glioma (Glioblastoma Multiforme)","High Grade Glioma","Glioma, Malignant","Brain Cancer",[173],{"trials":207,"activeCount":99},[],{"trials":209,"activeCount":99},[],{"trials":211,"activeCount":99},[],{"intervention":85,"totalTrials":112,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":226,"PHASE4":228,"NA":230},{"trials":215,"activeCount":99},[],{"trials":217,"activeCount":99},[],{"trials":219,"activeCount":112,"soonestReadout":84},[220],{"nctId":82,"briefTitle":83,"status":105,"phases":221,"primaryCompletion":84,"completion":84,"start":187,"enrollment":222,"conditions":223,"interventions":225},[89],24,[224],"Progressive Multifocal Leukoencephalopathy",[85],{"trials":227,"activeCount":99},[],{"trials":229,"activeCount":99},[],{"trials":231,"activeCount":99},[],{"intervention":51,"totalTrials":112,"cells":233},{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":251,"PHASE4":253,"NA":255},{"trials":235,"activeCount":99},[],{"trials":237,"activeCount":99},[],{"trials":239,"activeCount":112,"soonestReadout":50},[240],{"nctId":48,"briefTitle":49,"status":241,"phases":242,"primaryCompletion":50,"completion":50,"start":243,"enrollment":244,"conditions":245,"interventions":249},"ENROLLING_BY_INVITATION",[89],"2023-07-10",45,[246,247,248],"Systemic Inflammation","Neuroinflammation","Microvascular Thrombosis",[51,250],"IV immunoglobulin",{"trials":252,"activeCount":99},[],{"trials":254,"activeCount":99},[],{"trials":256,"activeCount":99},[],{"intervention":250,"totalTrials":112,"cells":258},{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":269,"PHASE4":271,"NA":273},{"trials":260,"activeCount":99},[],{"trials":262,"activeCount":99},[],{"trials":264,"activeCount":112,"soonestReadout":50},[265],{"nctId":48,"briefTitle":49,"status":241,"phases":266,"primaryCompletion":50,"completion":50,"start":243,"enrollment":244,"conditions":267,"interventions":268},[89],[246,247,248],[51,250],{"trials":270,"activeCount":99},[],{"trials":272,"activeCount":99},[],{"trials":274,"activeCount":99},[],{"intervention":61,"totalTrials":112,"cells":276},{"EARLY_PHASE1":277,"PHASE1":279,"PHASE2":281,"PHASE3":289,"PHASE4":291,"NA":293},{"trials":278,"activeCount":99},[],{"trials":280,"activeCount":99},[],{"trials":282,"activeCount":112,"soonestReadout":60},[283],{"nctId":58,"briefTitle":59,"status":105,"phases":284,"primaryCompletion":60,"completion":84,"start":285,"enrollment":222,"conditions":286,"interventions":288},[88,89],"2021-09-24",[287],"HAM\u002FTSP",[61],{"trials":290,"activeCount":99},[],{"trials":292,"activeCount":99},[],{"trials":294,"activeCount":99},[],{"intervention":41,"totalTrials":95,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":315,"PHASE3":317,"PHASE4":319,"NA":321},{"trials":298,"activeCount":99},[],{"trials":300,"activeCount":112,"soonestReadout":40},[301,310],{"nctId":302,"briefTitle":303,"status":118,"phases":304,"primaryCompletion":305,"completion":306,"start":307,"enrollment":9,"conditions":308,"interventions":309},"NCT01326715","Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis",[88],"2019-09-18","2022-09-13","2013-10-17",[26],[41],{"nctId":38,"briefTitle":39,"status":105,"phases":311,"primaryCompletion":40,"completion":40,"start":312,"enrollment":188,"conditions":313,"interventions":314},[88],"2024-11-19",[20],[41],{"trials":316,"activeCount":99},[],{"trials":318,"activeCount":99},[],{"trials":320,"activeCount":99},[],{"trials":322,"activeCount":99},[],{"intervention":56,"totalTrials":112,"cells":324},{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":338,"PHASE3":340,"PHASE4":342,"NA":344},{"trials":326,"activeCount":99},[],{"trials":328,"activeCount":112,"soonestReadout":55},[329],{"nctId":53,"briefTitle":54,"status":330,"phases":331,"primaryCompletion":55,"completion":332,"start":333,"enrollment":108,"conditions":334,"interventions":337},"ACTIVE_NOT_RECRUITING",[88],"2028-09-30","2026-02-02",[335,336],"Amyotrophic Lateral Sclerosis","Motor Neuron Disease",[56],{"trials":339,"activeCount":99},[],{"trials":341,"activeCount":99},[],{"trials":343,"activeCount":99},[],{"trials":345,"activeCount":99},[],{"intervention":66,"totalTrials":112,"cells":347},{"EARLY_PHASE1":348,"PHASE1":350,"PHASE2":358,"PHASE3":360,"PHASE4":362,"NA":364},{"trials":349,"activeCount":99},[],{"trials":351,"activeCount":112,"soonestReadout":65},[352],{"nctId":63,"briefTitle":64,"status":159,"phases":353,"primaryCompletion":65,"completion":65,"start":187,"enrollment":354,"conditions":355,"interventions":357},[88],15,[356],"Post-Acute COVID-19 Syndrome",[66],{"trials":359,"activeCount":99},[],{"trials":361,"activeCount":99},[],{"trials":363,"activeCount":99},[],{"trials":365,"activeCount":99},[],{"intervention":367,"totalTrials":112,"cells":368},"89 Zr-Df-crefmirlimab",{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":383,"PHASE3":385,"PHASE4":387,"NA":389},{"trials":370,"activeCount":99},[],{"trials":372,"activeCount":112,"soonestReadout":377},[373],{"nctId":374,"briefTitle":375,"status":105,"phases":376,"primaryCompletion":377,"completion":378,"start":379,"enrollment":354,"conditions":380,"interventions":382},"NCT05849467","Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy",[88],"2030-04-01","2030-12-01","2023-10-19",[224,26,381],"Other Neuroinflammatory Diseases With BBB Leakage",[367],{"trials":384,"activeCount":99},[],{"trials":386,"activeCount":99},[],{"trials":388,"activeCount":99},[],{"trials":390,"activeCount":99},[],{"intervention":80,"totalTrials":95,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":399,"PHASE4":401,"NA":403},{"trials":394,"activeCount":99},[],{"trials":396,"activeCount":99},[],{"trials":398,"activeCount":99},[],{"trials":400,"activeCount":99},[],{"trials":402,"activeCount":99},[],{"trials":404,"activeCount":112,"soonestReadout":75},[405,416],{"nctId":78,"briefTitle":79,"status":330,"phases":406,"primaryCompletion":75,"completion":84,"start":407,"enrollment":408,"conditions":409,"interventions":412},[],"2018-09-06",89,[28,410,411],"Multiple System Atrophy","Autonomic Failure",[80,413,414,415],"18F-DOPA","11C-Methylreboxetine","18F-Dopamine",{"nctId":417,"briefTitle":418,"status":118,"phases":419,"primaryCompletion":420,"completion":420,"start":421,"enrollment":408,"conditions":422,"interventions":425},"NCT00775853","Biomarkers of Risk of Parkinson Disease",[],"2023-01-11","2009-05-27",[17,423,424],"Autonomic Nervous System Diseases","Pure Autonomic Failure",[426,427,80],"6-[18F]Fluorodopamine","6-[18F]Fluorodopa",{"intervention":71,"totalTrials":112,"cells":429},{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":436,"PHASE4":438,"NA":440},{"trials":431,"activeCount":99},[],{"trials":433,"activeCount":99},[],{"trials":435,"activeCount":99},[],{"trials":437,"activeCount":99},[],{"trials":439,"activeCount":99},[],{"trials":441,"activeCount":112,"soonestReadout":70},[442],{"nctId":68,"briefTitle":69,"status":105,"phases":443,"primaryCompletion":70,"completion":70,"start":444,"enrollment":445,"conditions":446,"interventions":449},[92],"2026-03-09",22,[447,448],"Cushing's Disease","Pituitary Adenoma",[71],{"intervention":413,"totalTrials":112,"cells":451},{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":460,"NA":462},{"trials":453,"activeCount":99},[],{"trials":455,"activeCount":99},[],{"trials":457,"activeCount":99},[],{"trials":459,"activeCount":99},[],{"trials":461,"activeCount":99},[],{"trials":463,"activeCount":112,"soonestReadout":75},[464],{"nctId":78,"briefTitle":79,"status":330,"phases":465,"primaryCompletion":75,"completion":84,"start":407,"enrollment":408,"conditions":466,"interventions":467},[],[28,410,411],[80,413,414,415],{"intervention":414,"totalTrials":112,"cells":469},{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":474,"PHASE3":476,"PHASE4":478,"NA":480},{"trials":471,"activeCount":99},[],{"trials":473,"activeCount":99},[],{"trials":475,"activeCount":99},[],{"trials":477,"activeCount":99},[],{"trials":479,"activeCount":99},[],{"trials":481,"activeCount":112,"soonestReadout":75},[482],{"nctId":78,"briefTitle":79,"status":330,"phases":483,"primaryCompletion":75,"completion":84,"start":407,"enrollment":408,"conditions":484,"interventions":485},[],[28,410,411],[80,413,414,415],{"intervention":415,"totalTrials":112,"cells":487},{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":492,"PHASE3":494,"PHASE4":496,"NA":498},{"trials":489,"activeCount":99},[],{"trials":491,"activeCount":99},[],{"trials":493,"activeCount":99},[],{"trials":495,"activeCount":99},[],{"trials":497,"activeCount":99},[],{"trials":499,"activeCount":112,"soonestReadout":75},[500],{"nctId":78,"briefTitle":79,"status":330,"phases":501,"primaryCompletion":75,"completion":84,"start":407,"enrollment":408,"conditions":502,"interventions":503},[],[28,410,411],[80,413,414,415],{"intervention":505,"totalTrials":506,"cells":507},"Replagal",4,{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":523,"PHASE3":540,"PHASE4":542,"NA":552},{"trials":509,"activeCount":99},[],{"trials":511,"activeCount":99},[512],{"nctId":513,"briefTitle":514,"status":118,"phases":515,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":519,"interventions":521},"NCT00357786","An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease",[88],"2008-12","2003-10",3,[520],"Fabry Disease",[522,505],"Replagal agalsidase alfa",{"trials":524,"activeCount":99},[525,532],{"nctId":526,"briefTitle":527,"status":118,"phases":528,"completion":529,"start":517,"enrollment":32,"conditions":530,"interventions":531},"NCT00071877","An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease",[89],"2005-06",[520],[505],{"nctId":533,"briefTitle":534,"status":118,"phases":535,"completion":536,"start":537,"enrollment":32,"conditions":538,"interventions":539},"NCT00075244","Alternative Dosing and Regimen of Replagal to Treat Fabry Disease",[89],"2005-11","2004-01",[520],[505],{"trials":541,"activeCount":99},[],{"trials":543,"activeCount":99},[544],{"nctId":545,"briefTitle":546,"status":118,"phases":547,"completion":548,"start":549,"enrollment":32,"conditions":550,"interventions":551},"NCT00097890","Replagal Enzyme Replacement Therapy for Adults With Fabry Disease",[91],"2005-12","2004-11",[520],[505,505],{"trials":553,"activeCount":99},[],{"intervention":555,"totalTrials":518,"cells":556},"Aspirin",{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":561,"PHASE3":576,"PHASE4":590,"NA":600},{"trials":558,"activeCount":99},[],{"trials":560,"activeCount":99},[],{"trials":562,"activeCount":99},[563],{"nctId":564,"briefTitle":565,"status":118,"phases":566,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":571,"interventions":573},"NCT00061373","Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)",[89],"2009-12","2011-07","2003-05",18,[572],"Ischemic Stroke",[555,574,575],"tinzaparin sodium","eptifibatide",{"trials":577,"activeCount":99},[578],{"nctId":579,"briefTitle":580,"status":581,"phases":582,"completion":583,"conditions":584,"interventions":588},"NCT00004728","Aspirin Or Warfarin To Prevent Stroke","TERMINATED",[90],"2003-07",[23,585,586,587],"Cerebral Infarction","Atherosclerosis","Constriction, Pathologic",[589,555],"Warfarin",{"trials":591,"activeCount":99},[592],{"nctId":593,"briefTitle":594,"status":118,"phases":595,"conditions":596,"interventions":597},"NCT00004727","Antiplatelet Therapy to Prevent Stroke in African Americans",[91],[23,585],[598,599],"aspirin","ticlopidine",{"trials":601,"activeCount":99},[],{"intervention":603,"totalTrials":95,"cells":604},"Propranolol",{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":621,"PHASE4":623,"NA":632},{"trials":606,"activeCount":99},[],{"trials":608,"activeCount":99},[],{"trials":610,"activeCount":99},[611],{"nctId":612,"briefTitle":613,"status":118,"phases":614,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":620},"NCT00093860","Propranolol to Treat Fainting in Children With Sympathoadrenal Imbalance",[89],"2005-03","2004-10",50,[619],"Syncope",[603],{"trials":622,"activeCount":99},[],{"trials":624,"activeCount":99},[625],{"nctId":626,"briefTitle":627,"status":118,"phases":628,"completion":615,"start":569,"enrollment":222,"conditions":629,"interventions":631},"NCT00060866","Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance",[91],[630],"Neurocardiogenic Syncope",[603],{"trials":633,"activeCount":99},[],{"intervention":599,"totalTrials":112,"cells":635},{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":640,"PHASE3":642,"PHASE4":644,"NA":650},{"trials":637,"activeCount":99},[],{"trials":639,"activeCount":99},[],{"trials":641,"activeCount":99},[],{"trials":643,"activeCount":99},[],{"trials":645,"activeCount":99},[646],{"nctId":593,"briefTitle":594,"status":118,"phases":647,"conditions":648,"interventions":649},[91],[23,585],[598,599],{"trials":651,"activeCount":99},[],{"intervention":653,"totalTrials":112,"cells":654},"Donepezil",{"EARLY_PHASE1":655,"PHASE1":657,"PHASE2":659,"PHASE3":661,"PHASE4":663,"NA":673},{"trials":656,"activeCount":99},[],{"trials":658,"activeCount":99},[],{"trials":660,"activeCount":99},[],{"trials":662,"activeCount":99},[],{"trials":664,"activeCount":99},[665],{"nctId":666,"briefTitle":667,"status":118,"phases":668,"completion":615,"start":669,"enrollment":670,"conditions":671,"interventions":672},"NCT00030979","Donepezil to Treat Dementia in Parkinson's Disease",[91],"2002-02",28,[17],[653],{"trials":674,"activeCount":99},[],{"intervention":676,"totalTrials":95,"cells":677},"lorazepam",{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":694,"PHASE3":696,"PHASE4":709,"NA":711},{"trials":679,"activeCount":99},[],{"trials":681,"activeCount":99},[682],{"nctId":683,"briefTitle":684,"status":118,"phases":685,"primaryCompletion":686,"completion":686,"start":687,"enrollment":688,"conditions":689,"interventions":691},"NCT00055549","Dextromethorphan to Treat Patients With Voice Spasms",[88],"2009-11-13","2003-03-04",65,[690],"Voice Disorders",[692,693],"Dextromethorphan","Lorazepam",{"trials":695,"activeCount":99},[],{"trials":697,"activeCount":99},[698],{"nctId":699,"briefTitle":700,"status":118,"phases":701,"completion":702,"start":703,"enrollment":704,"conditions":705,"interventions":707},"NCT00004297","Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus",[90],"1999-02","1995-11",210,[706],"Status Epilepticus",[708,676],"diazepam",{"trials":710,"activeCount":99},[],{"trials":712,"activeCount":99},[],{"intervention":714,"totalTrials":112,"cells":715},"minocycline",{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":720,"PHASE3":722,"PHASE4":733,"NA":735},{"trials":717,"activeCount":99},[],{"trials":719,"activeCount":99},[],{"trials":721,"activeCount":99},[],{"trials":723,"activeCount":99},[724],{"nctId":725,"briefTitle":726,"status":118,"phases":727,"completion":728,"start":729,"enrollment":730,"conditions":731,"interventions":732},"NCT00047723","Minocycline to Treat Amyotrophic Lateral Sclerosis",[90],"2007-01","2003-01",400,[335],[714],{"trials":734,"activeCount":99},[],{"trials":736,"activeCount":99},[],{"intervention":589,"totalTrials":112,"cells":738},{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":745,"PHASE4":751,"NA":753},{"trials":740,"activeCount":99},[],{"trials":742,"activeCount":99},[],{"trials":744,"activeCount":99},[],{"trials":746,"activeCount":99},[747],{"nctId":579,"briefTitle":580,"status":581,"phases":748,"completion":583,"conditions":749,"interventions":750},[90],[23,585,586,587],[589,555],{"trials":752,"activeCount":99},[],{"trials":754,"activeCount":99},[],{"intervention":756,"totalTrials":112,"cells":757},"phenytoin",{"EARLY_PHASE1":758,"PHASE1":760,"PHASE2":762,"PHASE3":764,"PHASE4":777,"NA":779},{"trials":759,"activeCount":99},[],{"trials":761,"activeCount":99},[],{"trials":763,"activeCount":99},[],{"trials":765,"activeCount":99},[766],{"nctId":767,"briefTitle":768,"status":118,"phases":769,"start":770,"enrollment":771,"conditions":772,"interventions":775},"NCT00004817","Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures",[90],"1991-02",385,[773,774],"Post-Traumatic Seizure Disorder","Head Injuries",[756,776],"valproate sodium",{"trials":778,"activeCount":99},[],{"trials":780,"activeCount":99},[],{"intervention":776,"totalTrials":112,"cells":782},{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":789,"PHASE4":795,"NA":797},{"trials":784,"activeCount":99},[],{"trials":786,"activeCount":99},[],{"trials":788,"activeCount":99},[],{"trials":790,"activeCount":99},[791],{"nctId":767,"briefTitle":768,"status":118,"phases":792,"start":770,"enrollment":771,"conditions":793,"interventions":794},[90],[773,774],[756,776],{"trials":796,"activeCount":99},[],{"trials":798,"activeCount":99},[],{"intervention":127,"totalTrials":112,"cells":800},{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":813,"NA":815},{"trials":802,"activeCount":99},[],{"trials":804,"activeCount":99},[],{"trials":806,"activeCount":99},[],{"trials":808,"activeCount":99},[809],{"nctId":116,"briefTitle":117,"status":118,"phases":810,"primaryCompletion":120,"start":121,"enrollment":122,"conditions":811,"interventions":812},[90],[124],[126,127],{"trials":814,"activeCount":99},[],{"trials":816,"activeCount":99},[],{"intervention":818,"totalTrials":112,"cells":819},"immune globulin",{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":826,"PHASE4":837,"NA":839},{"trials":821,"activeCount":99},[],{"trials":823,"activeCount":99},[],{"trials":825,"activeCount":99},[],{"trials":827,"activeCount":99},[828],{"nctId":829,"briefTitle":830,"status":118,"phases":831,"primaryCompletion":832,"start":833,"enrollment":834,"conditions":835,"interventions":836},"NCT00004744","Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis",[90],"1998-09","1993-02",76,[26],[818],{"trials":838,"activeCount":99},[],{"trials":840,"activeCount":99},[],{"intervention":708,"totalTrials":112,"cells":842},{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":849,"PHASE4":855,"NA":857},{"trials":844,"activeCount":99},[],{"trials":846,"activeCount":99},[],{"trials":848,"activeCount":99},[],{"trials":850,"activeCount":99},[851],{"nctId":699,"briefTitle":700,"status":118,"phases":852,"completion":702,"start":703,"enrollment":704,"conditions":853,"interventions":854},[90],[706],[708,676],{"trials":856,"activeCount":99},[],{"trials":858,"activeCount":99},[],{"intervention":860,"totalTrials":112,"cells":861},"TransMID",{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":878,"NA":880},{"trials":863,"activeCount":99},[],{"trials":865,"activeCount":99},[],{"trials":867,"activeCount":99},[],{"trials":869,"activeCount":99},[870],{"nctId":871,"briefTitle":872,"status":118,"phases":873,"completion":536,"start":874,"enrollment":108,"conditions":875,"interventions":877},"NCT00088400","Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors",[90],"2004-07",[876],"Glioblastoma",[860],{"trials":879,"activeCount":99},[],{"trials":881,"activeCount":99},[],{"intervention":883,"totalTrials":112,"cells":884},"Modafinil",{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":889,"PHASE3":891,"PHASE4":902,"NA":904},{"trials":886,"activeCount":99},[],{"trials":888,"activeCount":99},[],{"trials":890,"activeCount":99},[],{"trials":892,"activeCount":99},[893],{"nctId":894,"briefTitle":895,"status":581,"phases":896,"completion":897,"start":898,"enrollment":108,"conditions":899,"interventions":901},"NCT00067496","Modafinil to Treat Fatigue in Post-Polio Syndrome",[90],"2006-08","2003-08",[900],"Postpoliomyelitis Syndrome",[883],{"trials":903,"activeCount":99},[],{"trials":905,"activeCount":99},[],{"intervention":907,"totalTrials":112,"cells":908},"methionine",{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":913,"PHASE3":915,"PHASE4":927,"NA":929},{"trials":910,"activeCount":99},[],{"trials":912,"activeCount":99},[],{"trials":914,"activeCount":99},[],{"trials":916,"activeCount":99},[917],{"nctId":918,"briefTitle":919,"status":118,"phases":920,"enrollment":921,"conditions":922,"interventions":926},"NCT00032695","Treatment of AIDS Vacuolar Myelopathy With Methionine",[90],56,[923,924,925],"Myelopathy","AIDS-Myelopathy","AIDS Vacuolar Myelopathy",[907],{"trials":928,"activeCount":99},[],{"trials":930,"activeCount":99},[],{"intervention":932,"totalTrials":112,"cells":933},"levodopa",{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":938,"PHASE3":940,"PHASE4":950,"NA":952},{"trials":935,"activeCount":99},[],{"trials":937,"activeCount":99},[],{"trials":939,"activeCount":99},[],{"trials":941,"activeCount":99},[942],{"nctId":943,"briefTitle":944,"status":118,"phases":945,"completion":946,"start":947,"conditions":948,"interventions":949},"NCT00004733","Timing of Levodopa Treatment in Parkinson's Disease",[90],"2004-02","1998-01",[28],[932],{"trials":951,"activeCount":99},[],{"trials":953,"activeCount":99},[],{"intervention":955,"totalTrials":112,"cells":956},"pyridoxine",{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":963,"PHASE4":975,"NA":977},{"trials":958,"activeCount":99},[],{"trials":960,"activeCount":99},[],{"trials":962,"activeCount":99},[],{"trials":964,"activeCount":99},[965],{"nctId":966,"briefTitle":967,"status":118,"phases":968,"completion":946,"start":969,"conditions":970,"interventions":972},"NCT00004734","Vitamin Therapy for Prevention of Stroke",[90],"1996-09",[23,585,971],"Myocardial Infarction",[955,973,974],"cyanocobalamin","folic acid multivitamin",{"trials":976,"activeCount":99},[],{"trials":978,"activeCount":99},[],{"intervention":973,"totalTrials":112,"cells":980},{"EARLY_PHASE1":981,"PHASE1":983,"PHASE2":985,"PHASE3":987,"PHASE4":993,"NA":995},{"trials":982,"activeCount":99},[],{"trials":984,"activeCount":99},[],{"trials":986,"activeCount":99},[],{"trials":988,"activeCount":99},[989],{"nctId":966,"briefTitle":967,"status":118,"phases":990,"completion":946,"start":969,"conditions":991,"interventions":992},[90],[23,585,971],[955,973,974],{"trials":994,"activeCount":99},[],{"trials":996,"activeCount":99},[],{"intervention":974,"totalTrials":112,"cells":998},{"EARLY_PHASE1":999,"PHASE1":1001,"PHASE2":1003,"PHASE3":1005,"PHASE4":1011,"NA":1013},{"trials":1000,"activeCount":99},[],{"trials":1002,"activeCount":99},[],{"trials":1004,"activeCount":99},[],{"trials":1006,"activeCount":99},[1007],{"nctId":966,"briefTitle":967,"status":118,"phases":1008,"completion":946,"start":969,"conditions":1009,"interventions":1010},[90],[23,585,971],[955,973,974],{"trials":1012,"activeCount":99},[],{"trials":1014,"activeCount":99},[],{"intervention":1016,"totalTrials":1017,"cells":1018},"IV Levodopa",5,{"EARLY_PHASE1":1019,"PHASE1":1021,"PHASE2":1023,"PHASE3":1071,"PHASE4":1073,"NA":1075},{"trials":1020,"activeCount":99},[],{"trials":1022,"activeCount":99},[],{"trials":1024,"activeCount":99},[1025,1033,1042,1051,1061],{"nctId":1026,"briefTitle":1027,"status":118,"phases":1028,"completion":615,"start":1029,"enrollment":1030,"conditions":1031,"interventions":1032},"NCT00013624","Riluzole to Treat Parkinson's Disease",[89],"2001-03",20,[28],[1016],{"nctId":1034,"briefTitle":1035,"status":118,"phases":1036,"completion":1037,"start":1038,"enrollment":108,"conditions":1039,"interventions":1040},"NCT00009048","EMD 128130 for the Treatment of Parkinson's Disease",[89],"2003-12","2001-01",[28],[1041,1016],"EMD 128130",{"nctId":1043,"briefTitle":1044,"status":118,"phases":1045,"completion":1046,"start":1047,"enrollment":188,"conditions":1048,"interventions":1049},"NCT00108667","Talampanel to Treat Parkinson's Disease",[89],"2006-02","2005-04",[17],[1016,1050],"Talampanel",{"nctId":1052,"briefTitle":1053,"status":118,"phases":1054,"completion":1055,"start":1056,"enrollment":1057,"conditions":1058,"interventions":1059},"NCT00006337","KW-6002 to Treat Parkinson's Disease",[89],"2002-01","2000-10",16,[28],[1060,1016],"KW-6002",{"nctId":1062,"briefTitle":1063,"status":118,"phases":1064,"completion":1065,"start":1066,"enrollment":108,"conditions":1067,"interventions":1068},"NCT00040209","JP-1730 to Treat Parkinson's Disease",[89],"2005-07","2002-06",[17],[1069,1016,1070],"JP 1730","IV Apomorphine",{"trials":1072,"activeCount":99},[],{"trials":1074,"activeCount":99},[],{"trials":1076,"activeCount":99},[],{"intervention":1078,"totalTrials":506,"cells":1079},"1-Octanol",{"EARLY_PHASE1":1080,"PHASE1":1082,"PHASE2":1101,"PHASE3":1119,"PHASE4":1121,"NA":1123},{"trials":1081,"activeCount":99},[],{"trials":1083,"activeCount":99},[1084,1093],{"nctId":1085,"briefTitle":1086,"status":118,"phases":1087,"completion":1038,"start":1088,"enrollment":1089,"conditions":1090,"interventions":1092},"NCT00001986","1-Octanol to Treat Essential Tremor",[88],"2000-01",12,[1091],"Essential Tremor",[1078],{"nctId":1094,"briefTitle":1086,"status":118,"phases":1095,"completion":1096,"start":1097,"enrollment":1098,"conditions":1099,"interventions":1100},"NCT00016679",[88],"2004-03","2001-05",42,[1091],[1078],{"trials":1102,"activeCount":99},[1103,1111],{"nctId":1104,"briefTitle":1105,"status":118,"phases":1106,"completion":1107,"start":1096,"enrollment":1108,"conditions":1109,"interventions":1110},"NCT00080366","Octanol to Treat Essential Tremor",[89],"2007-03",14,[1091],[1078],{"nctId":1112,"briefTitle":1113,"status":118,"phases":1114,"primaryCompletion":1115,"completion":1115,"start":1116,"enrollment":35,"conditions":1117,"interventions":1118},"NCT00102596","Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor",[89],"2009-09","2005-01",[1091],[1078],{"trials":1120,"activeCount":99},[],{"trials":1122,"activeCount":99},[],{"trials":1124,"activeCount":99},[],{"intervention":1126,"totalTrials":518,"cells":1127},"Intravenous Levodopa",{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1132,"PHASE3":1160,"PHASE4":1162,"NA":1164},{"trials":1129,"activeCount":99},[],{"trials":1131,"activeCount":99},[],{"trials":1133,"activeCount":99},[1134,1143,1153],{"nctId":1135,"briefTitle":1136,"status":118,"phases":1137,"completion":1138,"start":1139,"enrollment":188,"conditions":1140,"interventions":1141},"NCT00089622","Lisuride Patch to Treat Parkinson's Disease",[89],"2007-03-31","2004-08-04",[17],[1126,1142],"Lisuride Transdermal System",{"nctId":1144,"briefTitle":1145,"status":118,"phases":1146,"completion":1147,"start":1148,"enrollment":188,"conditions":1149,"interventions":1151},"NCT00086294","ACP-103 to Treat Parkinson's Disease",[89],"2007-11-15","2004-06-25",[28,1150],"Dyskinesias",[1126,1152],"ACP-103",{"nctId":1154,"briefTitle":1155,"status":118,"phases":1156,"completion":1157,"start":537,"enrollment":188,"conditions":1158,"interventions":1159},"NCT00076674","Levetiracetam Treatment of L-dopa Induced Dyskinesias",[89],"2005-10",[1150,17],[1126],{"trials":1161,"activeCount":99},[],{"trials":1163,"activeCount":99},[],{"trials":1165,"activeCount":99},[],{"intervention":1167,"totalTrials":518,"cells":1168},"Rituximab",{"EARLY_PHASE1":1169,"PHASE1":1171,"PHASE2":1173,"PHASE3":1204,"PHASE4":1206,"NA":1208},{"trials":1170,"activeCount":99},[],{"trials":1172,"activeCount":99},[],{"trials":1174,"activeCount":99},[1175,1186,1195],{"nctId":1176,"briefTitle":1177,"status":118,"phases":1178,"primaryCompletion":1179,"completion":1180,"start":1181,"enrollment":222,"conditions":1182,"interventions":1184},"NCT00091897","Rituximab to Treat Stiff Person Syndrome",[89],"2007-07","2009-05","2004-09",[1183],"Stiff Person Syndrome",[1167,1185],"rituximab or placebo",{"nctId":1187,"briefTitle":1188,"status":118,"phases":1189,"completion":1190,"start":1191,"enrollment":108,"conditions":1192,"interventions":1194},"NCT00050245","Rituximab to Treat Neuropathy With Anti-MAG Antibodies",[89],"2007-10-17","2002-11-27",[1193],"Polyneuropathies",[1167],{"nctId":1196,"briefTitle":1197,"status":581,"phases":1198,"primaryCompletion":1199,"completion":1199,"start":1200,"enrollment":1201,"conditions":1202,"interventions":1203},"NCT01212094","Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)",[88,89],"2015-12","2010-09",44,[26],[1167],{"trials":1205,"activeCount":99},[],{"trials":1207,"activeCount":99},[],{"trials":1209,"activeCount":99},[],{"intervention":1211,"totalTrials":518,"cells":1212},"Idebenone",{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1232,"PHASE3":1243,"PHASE4":1245,"NA":1247},{"trials":1214,"activeCount":99},[],{"trials":1216,"activeCount":99},[1217,1226],{"nctId":1218,"briefTitle":1219,"status":118,"phases":1220,"completion":1221,"start":1097,"enrollment":1222,"conditions":1223,"interventions":1225},"NCT00015808","Safety Study of Idebenone to Treat Friedreich's Ataxia",[88],"2006-04",100,[1224],"Friedreich Ataxia",[1211],{"nctId":1227,"briefTitle":1228,"status":118,"phases":1229,"completion":1221,"start":946,"enrollment":1057,"conditions":1230,"interventions":1231},"NCT00078481","Phase 1 Trial of Idebenone to Treat Patients With Friedreich's Ataxia",[88],[1224],[1211],{"trials":1233,"activeCount":99},[1234],{"nctId":1235,"briefTitle":1236,"status":118,"phases":1237,"primaryCompletion":1238,"completion":1238,"start":1239,"enrollment":1240,"conditions":1241,"interventions":1242},"NCT00229632","Idebenone to Treat Friedreich's Ataxia",[89],"2007-12-17","2005-09-27",51,[1224],[1211],{"trials":1244,"activeCount":99},[],{"trials":1246,"activeCount":99},[],{"trials":1248,"activeCount":99},[],{"intervention":1250,"totalTrials":95,"cells":1251},"dextromethorphan",{"EARLY_PHASE1":1252,"PHASE1":1254,"PHASE2":1260,"PHASE3":1271,"PHASE4":1273,"NA":1275},{"trials":1253,"activeCount":99},[],{"trials":1255,"activeCount":99},[1256],{"nctId":683,"briefTitle":684,"status":118,"phases":1257,"primaryCompletion":686,"completion":686,"start":687,"enrollment":688,"conditions":1258,"interventions":1259},[88],[690],[692,693],{"trials":1261,"activeCount":99},[1262],{"nctId":1263,"briefTitle":1264,"status":118,"phases":1265,"completion":1266,"start":1267,"enrollment":1098,"conditions":1268,"interventions":1270},"NCT00001365","Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System",[89],"2001-06","1993-07",[1269,28],"Neurodegenerative Disease",[1250],{"trials":1272,"activeCount":99},[],{"trials":1274,"activeCount":99},[],{"trials":1276,"activeCount":99},[],{"intervention":1278,"totalTrials":95,"cells":1279},"Divalproex",{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1284,"PHASE3":1302,"PHASE4":1304,"NA":1306},{"trials":1281,"activeCount":99},[],{"trials":1283,"activeCount":99},[],{"trials":1285,"activeCount":99},[1286,1295],{"nctId":1287,"briefTitle":1288,"status":118,"phases":1289,"completion":615,"start":874,"enrollment":1290,"conditions":1291,"interventions":1293},"NCT00088387","Effect of Lithium and Divalproex in Alzheimer's Disease",[89],35,[1292],"Alzheimer Disease",[1278,1294],"Lithium",{"nctId":1296,"briefTitle":1297,"status":118,"phases":1298,"completion":615,"start":616,"enrollment":1290,"conditions":1299,"interventions":1301},"NCT00095355","Effects of Lithium and Divalproex'on Brain-Derived Neurotrophic Factor in Huntington's Disease",[89],[1300],"Huntington's Disease",[1294,1278],{"trials":1303,"activeCount":99},[],{"trials":1305,"activeCount":99},[],{"trials":1307,"activeCount":99},[],{"intervention":1294,"totalTrials":95,"cells":1309},{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1324,"PHASE4":1326,"NA":1328},{"trials":1311,"activeCount":99},[],{"trials":1313,"activeCount":99},[],{"trials":1315,"activeCount":99},[1316,1320],{"nctId":1287,"briefTitle":1288,"status":118,"phases":1317,"completion":615,"start":874,"enrollment":1290,"conditions":1318,"interventions":1319},[89],[1292],[1278,1294],{"nctId":1296,"briefTitle":1297,"status":118,"phases":1321,"completion":615,"start":616,"enrollment":1290,"conditions":1322,"interventions":1323},[89],[1300],[1294,1278],{"trials":1325,"activeCount":99},[],{"trials":1327,"activeCount":99},[],{"trials":1329,"activeCount":99},[],{"intervention":1331,"totalTrials":95,"cells":1332},"Vorinostat",{"EARLY_PHASE1":1333,"PHASE1":1335,"PHASE2":1347,"PHASE3":1357,"PHASE4":1359,"NA":1361},{"trials":1334,"activeCount":99},[],{"trials":1336,"activeCount":99},[1337],{"nctId":1338,"briefTitle":1339,"status":118,"phases":1340,"primaryCompletion":1341,"completion":1341,"start":1342,"enrollment":1343,"conditions":1344,"interventions":1346},"NCT02108002","Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)",[88],"2018-09-12","2014-04-05",7,[1345],"Von Hippel-Lindau Disease",[1331],{"trials":1348,"activeCount":99},[1349],{"nctId":1350,"briefTitle":1351,"status":1352,"phases":1353,"primaryCompletion":1354,"completion":1354,"start":1354,"enrollment":99,"conditions":1355,"interventions":1356},"NCT04339751","Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease","WITHDRAWN",[89],"2025-04-11",[447],[1331],{"trials":1358,"activeCount":99},[],{"trials":1360,"activeCount":99},[],{"trials":1362,"activeCount":99},[],{"intervention":1364,"totalTrials":95,"cells":1365},"Anakinra",{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1380,"PHASE3":1391,"PHASE4":1393,"NA":1395},{"trials":1367,"activeCount":99},[],{"trials":1369,"activeCount":99},[1370],{"nctId":1371,"briefTitle":1372,"status":581,"phases":1373,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":112,"conditions":1376,"interventions":1379},"NCT02527460","Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection",[88],"2018-03-02","2015-08-17",[1377,1378],"HIV Infections","Neurologic Disorders",[1364],{"trials":1381,"activeCount":99},[1382],{"nctId":1383,"briefTitle":1384,"status":118,"phases":1385,"primaryCompletion":1386,"completion":1386,"start":1387,"enrollment":1388,"conditions":1389,"interventions":1390},"NCT04025554","Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis",[88,89],"2023-10-24","2019-10-25",8,[26],[1364],{"trials":1392,"activeCount":99},[],{"trials":1394,"activeCount":99},[],{"trials":1396,"activeCount":99},[],{"intervention":1398,"totalTrials":95,"cells":1399},"Octanoic Acid",{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1412,"PHASE3":1423,"PHASE4":1425,"NA":1427},{"trials":1401,"activeCount":99},[],{"trials":1403,"activeCount":99},[1404],{"nctId":1405,"briefTitle":1406,"status":118,"phases":1407,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":570,"conditions":1410,"interventions":1411},"NCT01468948","Octanoic Acid for Essential Tremor",[88],"2012-07-18","2011-10-28",[1091],[1398],{"trials":1413,"activeCount":99},[1414],{"nctId":1415,"briefTitle":1416,"status":118,"phases":1417,"primaryCompletion":1418,"completion":1418,"start":1419,"enrollment":1420,"conditions":1421,"interventions":1422},"NCT00848172","Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor",[88,89],"2010-11","2009-02",29,[1091],[1398],{"trials":1424,"activeCount":99},[],{"trials":1426,"activeCount":99},[],{"trials":1428,"activeCount":99},[],{"intervention":1050,"totalTrials":95,"cells":1430},{"EARLY_PHASE1":1431,"PHASE1":1433,"PHASE2":1435,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1432,"activeCount":99},[],{"trials":1434,"activeCount":99},[],{"trials":1436,"activeCount":99},[1437,1445],{"nctId":1438,"briefTitle":1439,"status":118,"phases":1440,"completion":1441,"start":1442,"enrollment":32,"conditions":1443,"interventions":1444},"NCT00057460","Effect of Talampanel (an AMPA Receptor Blocker) on Brain Activity",[89],"2006-05","2003-04",[14],[1050],{"nctId":1043,"briefTitle":1044,"status":118,"phases":1446,"completion":1046,"start":1047,"enrollment":188,"conditions":1447,"interventions":1448},[89],[17],[1016,1050],{"trials":1450,"activeCount":99},[],{"trials":1452,"activeCount":99},[],{"trials":1454,"activeCount":99},[],{"intervention":1456,"totalTrials":112,"cells":1457},"Daclizumab",{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1462,"PHASE3":1474,"PHASE4":1476,"NA":1478},{"trials":1459,"activeCount":99},[],{"trials":1461,"activeCount":99},[],{"trials":1463,"activeCount":99},[1464],{"nctId":1465,"briefTitle":1466,"status":118,"phases":1467,"primaryCompletion":1468,"completion":1469,"start":1470,"enrollment":1057,"conditions":1471,"interventions":1473},"NCT00071838","Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis",[89],"2007-10-04","2011-08-16","2003-10-30",[1472],"Multiple Sclerosis, Relapsing-Remitting",[1456],{"trials":1475,"activeCount":99},[],{"trials":1477,"activeCount":99},[],{"trials":1479,"activeCount":99},[],{"intervention":1481,"totalTrials":112,"cells":1482},"Droxidopa",{"EARLY_PHASE1":1483,"PHASE1":1485,"PHASE2":1487,"PHASE3":1499,"PHASE4":1501,"NA":1503},{"trials":1484,"activeCount":99},[],{"trials":1486,"activeCount":99},[],{"trials":1488,"activeCount":99},[1489],{"nctId":1490,"briefTitle":1491,"status":581,"phases":1492,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":1108,"conditions":1495,"interventions":1496},"NCT00547911","Augmenting Effects of L-DOPS With Carbidopa and Entacapone",[88,89],"2013-04","2007-10",[17,410,423],[1481,1497,1498],"Carbidopa","Entacapone",{"trials":1500,"activeCount":99},[],{"trials":1502,"activeCount":99},[],{"trials":1504,"activeCount":99},[],{"intervention":1497,"totalTrials":112,"cells":1506},{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1517,"PHASE4":1519,"NA":1521},{"trials":1508,"activeCount":99},[],{"trials":1510,"activeCount":99},[],{"trials":1512,"activeCount":99},[1513],{"nctId":1490,"briefTitle":1491,"status":581,"phases":1514,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":1108,"conditions":1515,"interventions":1516},[88,89],[17,410,423],[1481,1497,1498],{"trials":1518,"activeCount":99},[],{"trials":1520,"activeCount":99},[],{"trials":1522,"activeCount":99},[],{"intervention":1498,"totalTrials":112,"cells":1524},{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1529,"PHASE3":1535,"PHASE4":1537,"NA":1539},{"trials":1526,"activeCount":99},[],{"trials":1528,"activeCount":99},[],{"trials":1530,"activeCount":99},[1531],{"nctId":1490,"briefTitle":1491,"status":581,"phases":1532,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":1108,"conditions":1533,"interventions":1534},[88,89],[17,410,423],[1481,1497,1498],{"trials":1536,"activeCount":99},[],{"trials":1538,"activeCount":99},[],{"trials":1540,"activeCount":99},[],{"intervention":1542,"totalTrials":112,"cells":1543},"Rolipram",{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1548,"PHASE3":1559,"PHASE4":1561,"NA":1563},{"trials":1545,"activeCount":99},[],{"trials":1547,"activeCount":99},[],{"trials":1549,"activeCount":99},[1550],{"nctId":1551,"briefTitle":1552,"status":118,"phases":1553,"completion":1554,"start":1555,"enrollment":1556,"conditions":1557,"interventions":1558},"NCT00011375","Rolipram to Treat Multiple Sclerosis",[89],"2004-04","2001-02",52,[26],[1542],{"trials":1560,"activeCount":99},[],{"trials":1562,"activeCount":99},[],{"trials":1564,"activeCount":99},[],{"intervention":1566,"totalTrials":112,"cells":1567},"LY300164",{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1582,"PHASE4":1584,"NA":1586},{"trials":1569,"activeCount":99},[],{"trials":1571,"activeCount":99},[],{"trials":1573,"activeCount":99},[1574],{"nctId":1575,"briefTitle":1576,"status":118,"phases":1577,"completion":1578,"start":1579,"enrollment":1030,"conditions":1580,"interventions":1581},"NCT00004576","Study of LY300164 for the Treatment of Parkinson's Disease",[89],"2000-08","2000-02",[1150,17],[1566],{"trials":1583,"activeCount":99},[],{"trials":1585,"activeCount":99},[],{"trials":1587,"activeCount":99},[],{"intervention":1142,"totalTrials":112,"cells":1589},{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1594,"PHASE3":1600,"PHASE4":1602,"NA":1604},{"trials":1591,"activeCount":99},[],{"trials":1593,"activeCount":99},[],{"trials":1595,"activeCount":99},[1596],{"nctId":1135,"briefTitle":1136,"status":118,"phases":1597,"completion":1138,"start":1139,"enrollment":188,"conditions":1598,"interventions":1599},[89],[17],[1126,1142],{"trials":1601,"activeCount":99},[],{"trials":1603,"activeCount":99},[],{"trials":1605,"activeCount":99},[],{"intervention":1607,"totalTrials":112,"cells":1608},"Reopro",{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1613,"PHASE3":1625,"PHASE4":1627,"NA":1629},{"trials":1610,"activeCount":99},[],{"trials":1612,"activeCount":99},[],{"trials":1614,"activeCount":99},[1615],{"nctId":1616,"briefTitle":1617,"status":118,"phases":1618,"primaryCompletion":1619,"completion":1619,"start":1620,"enrollment":1621,"conditions":1622,"interventions":1623},"NCT00046293","ReoPro and Retavase to Treat Acute Stroke",[89],"2007-07-20","2002-09-24",72,[31],[1607,1624],"Retrovase",{"trials":1626,"activeCount":99},[],{"trials":1628,"activeCount":99},[],{"trials":1630,"activeCount":99},[],{"intervention":1624,"totalTrials":112,"cells":1632},{"EARLY_PHASE1":1633,"PHASE1":1635,"PHASE2":1637,"PHASE3":1643,"PHASE4":1645,"NA":1647},{"trials":1634,"activeCount":99},[],{"trials":1636,"activeCount":99},[],{"trials":1638,"activeCount":99},[1639],{"nctId":1616,"briefTitle":1617,"status":118,"phases":1640,"primaryCompletion":1619,"completion":1619,"start":1620,"enrollment":1621,"conditions":1641,"interventions":1642},[89],[31],[1607,1624],{"trials":1644,"activeCount":99},[],{"trials":1646,"activeCount":99},[],{"trials":1648,"activeCount":99},[],{"intervention":1650,"totalTrials":112,"cells":1651},"Zenapax",{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1656,"PHASE3":1667,"PHASE4":1669,"NA":1671},{"trials":1653,"activeCount":99},[],{"trials":1655,"activeCount":99},[],{"trials":1657,"activeCount":99},[1658],{"nctId":1659,"briefTitle":1660,"status":118,"phases":1661,"primaryCompletion":1662,"completion":1663,"start":1664,"enrollment":445,"conditions":1665,"interventions":1666},"NCT00001934","Zenapax to Treat Multiple Sclerosis",[89],"2005-08","2008-09","1999-09",[26],[1650],{"trials":1668,"activeCount":99},[],{"trials":1670,"activeCount":99},[],{"trials":1672,"activeCount":99},[],{"intervention":1674,"totalTrials":112,"cells":1675},"BoNT Injections",{"EARLY_PHASE1":1676,"PHASE1":1678,"PHASE2":1680,"PHASE3":1692,"PHASE4":1694,"NA":1696},{"trials":1677,"activeCount":99},[],{"trials":1679,"activeCount":99},[],{"trials":1681,"activeCount":99},[1682],{"nctId":1683,"briefTitle":1684,"status":118,"phases":1685,"primaryCompletion":1686,"completion":1686,"start":1687,"enrollment":1688,"conditions":1689,"interventions":1691},"NCT02015039","Pilot Trial of Botulinum Toxin and Occupational Therapy for Writer's Cramp",[88,89],"2016-09-13","2013-12-03",13,[1690],"Dystonia",[1674],{"trials":1693,"activeCount":99},[],{"trials":1695,"activeCount":99},[],{"trials":1697,"activeCount":99},[],{"intervention":1699,"totalTrials":112,"cells":1700},"CGP 77116",{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1715,"PHASE4":1717,"NA":1719},{"trials":1702,"activeCount":99},[],{"trials":1704,"activeCount":99},[],{"trials":1706,"activeCount":99},[1707],{"nctId":1708,"briefTitle":1709,"status":118,"phases":1710,"completion":1711,"start":1712,"enrollment":32,"conditions":1713,"interventions":1714},"NCT00001781","Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)",[89],"2002-03","1998-02",[26],[1699],{"trials":1716,"activeCount":99},[],{"trials":1718,"activeCount":99},[],{"trials":1720,"activeCount":99},[],{"intervention":1722,"totalTrials":112,"cells":1723},"Levetiracetam",{"EARLY_PHASE1":1724,"PHASE1":1726,"PHASE2":1728,"PHASE3":1740,"PHASE4":1742,"NA":1744},{"trials":1725,"activeCount":99},[],{"trials":1727,"activeCount":99},[],{"trials":1729,"activeCount":99},[1730],{"nctId":1731,"briefTitle":1732,"status":118,"phases":1733,"primaryCompletion":1734,"completion":1734,"start":1735,"enrollment":1388,"conditions":1736,"interventions":1739},"NCT02199509","Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia",[89],"2016-03","2014-07",[1737,1738],"Oromandibular Dystonia","Cranial Dystonia",[1722],{"trials":1741,"activeCount":99},[],{"trials":1743,"activeCount":99},[],{"trials":1745,"activeCount":99},[],{"intervention":1747,"totalTrials":112,"cells":1748},"growth hormone",{"EARLY_PHASE1":1749,"PHASE1":1751,"PHASE2":1753,"PHASE3":1765,"PHASE4":1767,"NA":1769},{"trials":1750,"activeCount":99},[],{"trials":1752,"activeCount":99},[],{"trials":1754,"activeCount":99},[1755],{"nctId":1756,"briefTitle":1757,"status":118,"phases":1758,"primaryCompletion":120,"start":1759,"enrollment":1760,"conditions":1761,"interventions":1763},"NCT00004275","Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner's Syndrome",[89],"1999-10",80,[1762],"Turner's Syndrome",[1747,1764],"oxandrolone",{"trials":1766,"activeCount":99},[],{"trials":1768,"activeCount":99},[],{"trials":1770,"activeCount":99},[],{"intervention":1764,"totalTrials":112,"cells":1772},{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1783,"PHASE4":1785,"NA":1787},{"trials":1774,"activeCount":99},[],{"trials":1776,"activeCount":99},[],{"trials":1778,"activeCount":99},[1779],{"nctId":1756,"briefTitle":1757,"status":118,"phases":1780,"primaryCompletion":120,"start":1759,"enrollment":1760,"conditions":1781,"interventions":1782},[89],[1762],[1747,1764],{"trials":1784,"activeCount":99},[],{"trials":1786,"activeCount":99},[],{"trials":1788,"activeCount":99},[],{"intervention":1790,"totalTrials":112,"cells":1791},"CX516",{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1796,"PHASE3":1807,"PHASE4":1809,"NA":1811},{"trials":1793,"activeCount":99},[],{"trials":1795,"activeCount":99},[],{"trials":1797,"activeCount":99},[1798],{"nctId":1799,"briefTitle":1800,"status":118,"phases":1801,"completion":536,"start":1802,"enrollment":188,"conditions":1803,"interventions":1806},"NCT00001662","Treatment of Alzheimer's Disease With CX516 (Ampalex)",[89],"1996-12",[1804,1805],"Alzheimer's Disease","Dementia",[1790],{"trials":1808,"activeCount":99},[],{"trials":1810,"activeCount":99},[],{"trials":1812,"activeCount":99},[],{"intervention":1814,"totalTrials":112,"cells":1815},"Alcohol",{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1832,"PHASE4":1834,"NA":1836},{"trials":1817,"activeCount":99},[],{"trials":1819,"activeCount":99},[],{"trials":1821,"activeCount":99},[1822],{"nctId":1823,"briefTitle":1824,"status":118,"phases":1825,"completion":1826,"start":1827,"enrollment":1828,"conditions":1829,"interventions":1831},"NCT00001925","Effect of Alcohol on Tremors",[89],"2002-07","1999-01",23,[1830],"Tremor",[1814],{"trials":1833,"activeCount":99},[],{"trials":1835,"activeCount":99},[],{"trials":1837,"activeCount":99},[],{"intervention":1839,"totalTrials":112,"cells":1840},"Amlodipine plus Botulinum toxin",{"EARLY_PHASE1":1841,"PHASE1":1843,"PHASE2":1845,"PHASE3":1855,"PHASE4":1857,"NA":1859},{"trials":1842,"activeCount":99},[],{"trials":1844,"activeCount":99},[],{"trials":1846,"activeCount":99},[1847],{"nctId":1848,"briefTitle":1849,"status":118,"phases":1850,"primaryCompletion":1851,"start":1852,"enrollment":1057,"conditions":1853,"interventions":1854},"NCT00015457","Amlodipine Plus Botulinum Toxin for Focal Dystonia",[89],"2009-04","2001-04",[34],[1839],{"trials":1856,"activeCount":99},[],{"trials":1858,"activeCount":99},[],{"trials":1860,"activeCount":99},[],{"intervention":1185,"totalTrials":112,"cells":1862},{"EARLY_PHASE1":1863,"PHASE1":1865,"PHASE2":1867,"PHASE3":1873,"PHASE4":1875,"NA":1877},{"trials":1864,"activeCount":99},[],{"trials":1866,"activeCount":99},[],{"trials":1868,"activeCount":99},[1869],{"nctId":1176,"briefTitle":1177,"status":118,"phases":1870,"primaryCompletion":1179,"completion":1180,"start":1181,"enrollment":222,"conditions":1871,"interventions":1872},[89],[1183],[1167,1185],{"trials":1874,"activeCount":99},[],{"trials":1876,"activeCount":99},[],{"trials":1878,"activeCount":99},[],{"intervention":1880,"totalTrials":112,"cells":1881},"Amantadine",{"EARLY_PHASE1":1882,"PHASE1":1884,"PHASE2":1886,"PHASE3":1896,"PHASE4":1898,"NA":1900},{"trials":1883,"activeCount":99},[],{"trials":1885,"activeCount":99},[],{"trials":1887,"activeCount":99},[1888],{"nctId":1889,"briefTitle":1890,"status":118,"phases":1891,"completion":1555,"start":1892,"enrollment":32,"conditions":1893,"interventions":1895},"NCT00001930","Treatment of Huntington's Chorea With Amantadine",[89],"1999-04",[1894,1300],"Chorea",[1880],{"trials":1897,"activeCount":99},[],{"trials":1899,"activeCount":99},[],{"trials":1901,"activeCount":99},[],{"intervention":1903,"totalTrials":112,"cells":1904},"E-Selectin nasal spray",{"EARLY_PHASE1":1905,"PHASE1":1907,"PHASE2":1909,"PHASE3":1919,"PHASE4":1921,"NA":1923},{"trials":1906,"activeCount":99},[],{"trials":1908,"activeCount":99},[],{"trials":1910,"activeCount":99},[1911],{"nctId":1912,"briefTitle":1913,"status":581,"phases":1914,"completion":946,"start":1029,"enrollment":1915,"conditions":1916,"interventions":1918},"NCT00012454","E-Selectin Nasal Spray to Prevent Stroke Recurrence",[89],60,[31,1917],"Transient Ischemic Attack",[1903],{"trials":1920,"activeCount":99},[],{"trials":1922,"activeCount":99},[],{"trials":1924,"activeCount":99},[],{"intervention":1926,"totalTrials":112,"cells":1927},"Nefiracetam",{"EARLY_PHASE1":1928,"PHASE1":1930,"PHASE2":1932,"PHASE3":1941,"PHASE4":1943,"NA":1945},{"trials":1929,"activeCount":99},[],{"trials":1931,"activeCount":99},[],{"trials":1933,"activeCount":99},[1934],{"nctId":1935,"briefTitle":1936,"status":118,"phases":1937,"completion":1055,"start":1938,"enrollment":617,"conditions":1939,"interventions":1940},"NCT00001933","Nefiracetam in the Treatment of Alzheimer's Disease",[89],"1999-07",[1804],[1926],{"trials":1942,"activeCount":99},[],{"trials":1944,"activeCount":99},[],{"trials":1946,"activeCount":99},[],{"intervention":1948,"totalTrials":112,"cells":1949},"Alemtuzumab",{"EARLY_PHASE1":1950,"PHASE1":1952,"PHASE2":1954,"PHASE3":1963,"PHASE4":1965,"NA":1967},{"trials":1951,"activeCount":99},[],{"trials":1953,"activeCount":99},[],{"trials":1955,"activeCount":99},[1956],{"nctId":1957,"briefTitle":1958,"status":118,"phases":1959,"primaryCompletion":1107,"completion":1107,"start":1096,"enrollment":1030,"conditions":1960,"interventions":1962},"NCT00079768","Alemtuzumab to Treat Sporadic Inclusion Body Myositis",[89],[1961],"Myositis, Inclusion Body",[1948],{"trials":1964,"activeCount":99},[],{"trials":1966,"activeCount":99},[],{"trials":1968,"activeCount":99},[],{"intervention":1970,"totalTrials":112,"cells":1971},"rhIGF-1",{"EARLY_PHASE1":1972,"PHASE1":1974,"PHASE2":1976,"PHASE3":1986,"PHASE4":1988,"NA":1990},{"trials":1973,"activeCount":99},[],{"trials":1975,"activeCount":99},[],{"trials":1977,"activeCount":99},[1978],{"nctId":1979,"briefTitle":1980,"status":118,"phases":1981,"completion":1982,"start":1983,"enrollment":354,"conditions":1984,"interventions":1985},"NCT00001669","A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect\u002FEfficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients",[89],"2000-04","1997-07",[26],[1970],{"trials":1987,"activeCount":99},[],{"trials":1989,"activeCount":99},[],{"trials":1991,"activeCount":99},[],{"intervention":1993,"totalTrials":112,"cells":1994},"Coenzyme Q10",{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":1999,"PHASE3":2007,"PHASE4":2009,"NA":2011},{"trials":1996,"activeCount":99},[],{"trials":1998,"activeCount":99},[],{"trials":2000,"activeCount":99},[2001],{"nctId":2002,"briefTitle":2003,"status":118,"phases":2004,"completion":517,"start":832,"conditions":2005,"interventions":2006},"NCT00004731","Parkinson's Disease Treatment With Coenzyme Q10",[89],[28],[1993],{"trials":2008,"activeCount":99},[],{"trials":2010,"activeCount":99},[],{"trials":2012,"activeCount":99},[],{"intervention":1152,"totalTrials":112,"cells":2014},{"EARLY_PHASE1":2015,"PHASE1":2017,"PHASE2":2019,"PHASE3":2025,"PHASE4":2027,"NA":2029},{"trials":2016,"activeCount":99},[],{"trials":2018,"activeCount":99},[],{"trials":2020,"activeCount":99},[2021],{"nctId":1144,"briefTitle":1145,"status":118,"phases":2022,"completion":1147,"start":1148,"enrollment":188,"conditions":2023,"interventions":2024},[89],[28,1150],[1126,1152],{"trials":2026,"activeCount":99},[],{"trials":2028,"activeCount":99},[],{"trials":2030,"activeCount":99},[],{"intervention":2032,"totalTrials":112,"cells":2033},"Eliprodil",{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2038,"PHASE3":2048,"PHASE4":2050,"NA":2052},{"trials":2035,"activeCount":99},[],{"trials":2037,"activeCount":99},[],{"trials":2039,"activeCount":99},[2040],{"nctId":2041,"briefTitle":2042,"status":118,"phases":2043,"completion":1038,"start":2044,"enrollment":1030,"conditions":2045,"interventions":2047},"NCT00001929","Treatment of Parkinson's Disease With Eliprodil",[89],"1999-03",[2046,17],"Movement Disorders",[2032],{"trials":2049,"activeCount":99},[],{"trials":2051,"activeCount":99},[],{"trials":2053,"activeCount":99},[],{"intervention":2055,"totalTrials":112,"cells":2056},"GDNF & Synchro Med Infusion System",{"EARLY_PHASE1":2057,"PHASE1":2059,"PHASE2":2061,"PHASE3":2072,"PHASE4":2074,"NA":2076},{"trials":2058,"activeCount":99},[],{"trials":2060,"activeCount":99},[],{"trials":2062,"activeCount":99},[2063],{"nctId":2064,"briefTitle":2065,"status":118,"phases":2066,"completion":2067,"start":2068,"enrollment":354,"conditions":2069,"interventions":2071},"NCT00005903","Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy",[89],"2005-05","2000-06",[2070],"Progressive Supranuclear Palsy",[2055],{"trials":2073,"activeCount":99},[],{"trials":2075,"activeCount":99},[],{"trials":2077,"activeCount":99},[],{"intervention":2079,"totalTrials":112,"cells":2080},"NS2330",{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2085,"PHASE3":2094,"PHASE4":2096,"NA":2098},{"trials":2082,"activeCount":99},[],{"trials":2084,"activeCount":99},[],{"trials":2086,"activeCount":99},[2087],{"nctId":2088,"briefTitle":2089,"status":118,"phases":2090,"completion":583,"start":1578,"enrollment":617,"conditions":2091,"interventions":2092},"NCT00006077","Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease",[89],[28],[2079,2093],"Levodopa and Domperidone",{"trials":2095,"activeCount":99},[],{"trials":2097,"activeCount":99},[],{"trials":2099,"activeCount":99},[],{"intervention":2093,"totalTrials":112,"cells":2101},{"EARLY_PHASE1":2102,"PHASE1":2104,"PHASE2":2106,"PHASE3":2112,"PHASE4":2114,"NA":2116},{"trials":2103,"activeCount":99},[],{"trials":2105,"activeCount":99},[],{"trials":2107,"activeCount":99},[2108],{"nctId":2088,"briefTitle":2089,"status":118,"phases":2109,"completion":583,"start":1578,"enrollment":617,"conditions":2110,"interventions":2111},[89],[28],[2079,2093],{"trials":2113,"activeCount":99},[],{"trials":2115,"activeCount":99},[],{"trials":2117,"activeCount":99},[],{"intervention":2119,"totalTrials":112,"cells":2120},"Intravenous Norepinephrine",{"EARLY_PHASE1":2121,"PHASE1":2123,"PHASE2":2125,"PHASE3":2137,"PHASE4":2139,"NA":2141},{"trials":2122,"activeCount":99},[],{"trials":2124,"activeCount":99},[],{"trials":2126,"activeCount":99},[2127],{"nctId":2128,"briefTitle":2129,"status":118,"phases":2130,"primaryCompletion":2131,"completion":2131,"start":2132,"enrollment":2133,"conditions":2134,"interventions":2136},"NCT01285908","Intravenous Norepinephrine for Orthostatic Hypotension",[88,89],"2012-09","2011-01",6,[2135],"Orthostatic Hypertension",[2119],{"trials":2138,"activeCount":99},[],{"trials":2140,"activeCount":99},[],{"trials":2142,"activeCount":99},[],{"intervention":2144,"totalTrials":112,"cells":2145},"Dutasteride",{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2150,"PHASE3":2162,"PHASE4":2164,"NA":2166},{"trials":2147,"activeCount":99},[],{"trials":2149,"activeCount":99},[],{"trials":2151,"activeCount":99},[2152],{"nctId":2153,"briefTitle":2154,"status":118,"phases":2155,"primaryCompletion":567,"completion":567,"start":2156,"enrollment":2157,"conditions":2158,"interventions":2161},"NCT00303446","Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)",[89],"2006-03",57,[2159,2160],"Kennedy's Disease","Spinal and Bulbar Muscular Atrophy",[2144],{"trials":2163,"activeCount":99},[],{"trials":2165,"activeCount":99},[],{"trials":2167,"activeCount":99},[],{"intervention":2169,"totalTrials":112,"cells":2170},"Erythropoeitin",{"EARLY_PHASE1":2171,"PHASE1":2173,"PHASE2":2175,"PHASE3":2186,"PHASE4":2188,"NA":2190},{"trials":2172,"activeCount":99},[],{"trials":2174,"activeCount":99},[],{"trials":2176,"activeCount":99},[2177],{"nctId":2178,"briefTitle":2179,"status":1352,"phases":2180,"primaryCompletion":2181,"completion":2181,"start":2182,"enrollment":99,"conditions":2183,"interventions":2185},"NCT02226848","Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in People With Persistent Symptoms During the Subacute Period After Traumatic Brain Injury",[89],"2017-05-31","2014-08-15",[2184],"Traumatic Brain Injury",[2169],{"trials":2187,"activeCount":99},[],{"trials":2189,"activeCount":99},[],{"trials":2191,"activeCount":99},[],{"intervention":2193,"totalTrials":112,"cells":2194},"Gamma Globulin",{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2199,"PHASE3":2212,"PHASE4":2214,"NA":2216},{"trials":2196,"activeCount":99},[],{"trials":2198,"activeCount":99},[],{"trials":2200,"activeCount":99},[2201],{"nctId":2202,"briefTitle":2203,"status":118,"phases":2204,"completion":1826,"start":2205,"enrollment":2206,"conditions":2207,"interventions":2211},"NCT00001261","Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies",[89],"1990-05",120,[2208,2209,2210],"Dermatomyositis","Inclusion Body Myositis","Polymyositis",[2193],{"trials":2213,"activeCount":99},[],{"trials":2215,"activeCount":99},[],{"trials":2217,"activeCount":99},[],{"intervention":2219,"totalTrials":112,"cells":2220},"Mexiletine",{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2225,"PHASE3":2236,"PHASE4":2238,"NA":2240},{"trials":2222,"activeCount":99},[],{"trials":2224,"activeCount":99},[],{"trials":2226,"activeCount":99},[2227],{"nctId":2228,"briefTitle":2229,"status":118,"phases":2230,"completion":1826,"start":2231,"enrollment":222,"conditions":2232,"interventions":2235},"NCT00001784","Mexiletine for the Treatment of Focal Dystonia",[89],"1998-07",[2233,1690,2234],"Blepharospasm","Spasm",[2219],{"trials":2237,"activeCount":99},[],{"trials":2239,"activeCount":99},[],{"trials":2241,"activeCount":99},[],{"intervention":2243,"totalTrials":112,"cells":2244},"intravenous immunoglobulin",{"EARLY_PHASE1":2245,"PHASE1":2247,"PHASE2":2249,"PHASE3":2260,"PHASE4":2262,"NA":2264},{"trials":2246,"activeCount":99},[],{"trials":2248,"activeCount":99},[],{"trials":2250,"activeCount":99},[2251],{"nctId":2252,"briefTitle":2253,"status":118,"phases":2254,"completion":1038,"start":2255,"enrollment":1915,"conditions":2256,"interventions":2259},"NCT00001287","Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",[89],"1990-12",[2257,2258],"Demyelinating Diseases","Paraproteinemias",[2243],{"trials":2261,"activeCount":99},[],{"trials":2263,"activeCount":99},[],{"trials":2265,"activeCount":99},[],{"intervention":2267,"totalTrials":112,"cells":2268},"ceftriaxone",{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2273,"PHASE3":2284,"PHASE4":2286,"NA":2288},{"trials":2270,"activeCount":99},[],{"trials":2272,"activeCount":99},[],{"trials":2274,"activeCount":99},[2275],{"nctId":2276,"briefTitle":2277,"status":118,"phases":2278,"start":2279,"enrollment":688,"conditions":2280,"interventions":2283},"NCT00037479","Brain Imaging and Retreatment Study of Persistent Lyme Disease",[89],"1999-12",[2281,2282],"Lyme Disease","Lyme Neuroborreliosis",[2267],{"trials":2285,"activeCount":99},[],{"trials":2287,"activeCount":99},[],{"trials":2289,"activeCount":99},[],{"intervention":574,"totalTrials":112,"cells":2291},{"EARLY_PHASE1":2292,"PHASE1":2294,"PHASE2":2296,"PHASE3":2302,"PHASE4":2304,"NA":2306},{"trials":2293,"activeCount":99},[],{"trials":2295,"activeCount":99},[],{"trials":2297,"activeCount":99},[2298],{"nctId":564,"briefTitle":565,"status":118,"phases":2299,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":2300,"interventions":2301},[89],[572],[555,574,575],{"trials":2303,"activeCount":99},[],{"trials":2305,"activeCount":99},[],{"trials":2307,"activeCount":99},[],{"intervention":575,"totalTrials":112,"cells":2309},{"EARLY_PHASE1":2310,"PHASE1":2312,"PHASE2":2314,"PHASE3":2320,"PHASE4":2322,"NA":2324},{"trials":2311,"activeCount":99},[],{"trials":2313,"activeCount":99},[],{"trials":2315,"activeCount":99},[2316],{"nctId":564,"briefTitle":565,"status":118,"phases":2317,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":2318,"interventions":2319},[89],[572],[555,574,575],{"trials":2321,"activeCount":99},[],{"trials":2323,"activeCount":99},[],{"trials":2325,"activeCount":99},[],{"intervention":2327,"totalTrials":112,"cells":2328},"PRX-00023",{"EARLY_PHASE1":2329,"PHASE1":2331,"PHASE2":2333,"PHASE3":2345,"PHASE4":2347,"NA":2349},{"trials":2330,"activeCount":99},[],{"trials":2332,"activeCount":99},[],{"trials":2334,"activeCount":99},[2335],{"nctId":2336,"briefTitle":2337,"status":581,"phases":2338,"primaryCompletion":2339,"completion":2339,"start":2340,"enrollment":1089,"conditions":2341,"interventions":2344},"NCT01281956","PRX-00023 Therapy in Localization-Related Epilepsy",[89],"2017-10-05","2011-01-07",[20,2342,2343],"Epilepsy, Temporal Lobe","Partial Epilepsy",[2327],{"trials":2346,"activeCount":99},[],{"trials":2348,"activeCount":99},[],{"trials":2350,"activeCount":99},[],{"intervention":2352,"totalTrials":112,"cells":2353},"Acetyl-Hexapeptide Topical Treatment",{"EARLY_PHASE1":2354,"PHASE1":2356,"PHASE2":2358,"PHASE3":2368,"PHASE4":2370,"NA":2372},{"trials":2355,"activeCount":99},[],{"trials":2357,"activeCount":99},[],{"trials":2359,"activeCount":99},[2360],{"nctId":2361,"briefTitle":2362,"status":118,"phases":2363,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":222,"conditions":2366,"interventions":2367},"NCT00942851","A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm",[88,89],"2010-10","2009-07",[34],[2352],{"trials":2369,"activeCount":99},[],{"trials":2371,"activeCount":99},[],{"trials":2373,"activeCount":99},[],{"intervention":2375,"totalTrials":112,"cells":2376},"Topical acetyl hexapeptide-8",{"EARLY_PHASE1":2377,"PHASE1":2379,"PHASE2":2381,"PHASE3":2391,"PHASE4":2393,"NA":2395},{"trials":2378,"activeCount":99},[],{"trials":2380,"activeCount":99},[],{"trials":2382,"activeCount":99},[2383],{"nctId":2384,"briefTitle":2385,"status":581,"phases":2386,"primaryCompletion":2387,"completion":2387,"start":2388,"enrollment":1388,"conditions":2389,"interventions":2390},"NCT01750346","Acetyl Hexapeptide-8 for Blepharospasm",[89],"2015-05","2012-11",[34],[2375],{"trials":2392,"activeCount":99},[],{"trials":2394,"activeCount":99},[],{"trials":2396,"activeCount":99},[],{"intervention":2398,"totalTrials":112,"cells":2399},"Buspirone",{"EARLY_PHASE1":2400,"PHASE1":2402,"PHASE2":2404,"PHASE3":2418,"PHASE4":2420,"NA":2422},{"trials":2401,"activeCount":99},[],{"trials":2403,"activeCount":99},[],{"trials":2405,"activeCount":99},[2406],{"nctId":2407,"briefTitle":2408,"status":581,"phases":2409,"primaryCompletion":2410,"completion":2410,"start":2411,"enrollment":2412,"conditions":2413,"interventions":2417},"NCT01496612","Buspirone Therapy for Localized Epilepsy",[89],"2016-04-19","2011-11-22",9,[2414,2415,20,2343,2416],"Anxiety Disorder","Seizures","Depression",[2398],{"trials":2419,"activeCount":99},[],{"trials":2421,"activeCount":99},[],{"trials":2423,"activeCount":99},[],{"intervention":2425,"totalTrials":112,"cells":2426},"prempro",{"EARLY_PHASE1":2427,"PHASE1":2429,"PHASE2":2431,"PHASE3":2441,"PHASE4":2443,"NA":2445},{"trials":2428,"activeCount":99},[],{"trials":2430,"activeCount":99},[],{"trials":2432,"activeCount":99},[2433],{"nctId":2434,"briefTitle":2435,"status":118,"phases":2436,"enrollment":2437,"conditions":2438,"interventions":2440},"NCT00027209","Hormone Replacement in Menopausal Women With Epilepsy",[89],125,[2439,20],"Menopause",[2425],{"trials":2442,"activeCount":99},[],{"trials":2444,"activeCount":99},[],{"trials":2446,"activeCount":99},[],{"intervention":2448,"totalTrials":112,"cells":2449},"tolebrutinib 60mg",{"EARLY_PHASE1":2450,"PHASE1":2452,"PHASE2":2454,"PHASE3":2467,"PHASE4":2469,"NA":2471},{"trials":2451,"activeCount":99},[],{"trials":2453,"activeCount":99},[],{"trials":2455,"activeCount":99},[2456],{"nctId":2457,"briefTitle":2458,"status":2459,"phases":2460,"primaryCompletion":2461,"completion":2462,"start":2463,"enrollment":1089,"conditions":2464,"interventions":2465},"NCT04742400","Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis","UNKNOWN",[89],"2023-06-15","2025-12-31","2021-04-15",[26],[2448,2466],"tolebrutinib 120mg",{"trials":2468,"activeCount":99},[],{"trials":2470,"activeCount":99},[],{"trials":2472,"activeCount":99},[],{"intervention":2466,"totalTrials":112,"cells":2474},{"EARLY_PHASE1":2475,"PHASE1":2477,"PHASE2":2479,"PHASE3":2485,"PHASE4":2487,"NA":2489},{"trials":2476,"activeCount":99},[],{"trials":2478,"activeCount":99},[],{"trials":2480,"activeCount":99},[2481],{"nctId":2457,"briefTitle":2458,"status":2459,"phases":2482,"primaryCompletion":2461,"completion":2462,"start":2463,"enrollment":1089,"conditions":2483,"interventions":2484},[89],[26],[2448,2466],{"trials":2486,"activeCount":99},[],{"trials":2488,"activeCount":99},[],{"trials":2490,"activeCount":99},[],{"intervention":2492,"totalTrials":112,"cells":2493},"OGT 918",{"EARLY_PHASE1":2494,"PHASE1":2496,"PHASE2":2498,"PHASE3":2509,"PHASE4":2511,"NA":2513},{"trials":2495,"activeCount":99},[],{"trials":2497,"activeCount":99},[],{"trials":2499,"activeCount":99},[2500],{"nctId":2501,"briefTitle":2502,"status":118,"phases":2503,"completion":2504,"start":2505,"enrollment":108,"conditions":2506,"interventions":2508},"NCT00041535","OGT 918-006: A Phase I\u002FII Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease",[89],"2007-03-21","2002-07-05",[2507],"Gaucher Disease",[2492],{"trials":2510,"activeCount":99},[],{"trials":2512,"activeCount":99},[],{"trials":2514,"activeCount":99},[],{"intervention":2516,"totalTrials":112,"cells":2517},"Botulinum Toxin A",{"EARLY_PHASE1":2518,"PHASE1":2520,"PHASE2":2522,"PHASE3":2533,"PHASE4":2535,"NA":2537},{"trials":2519,"activeCount":99},[],{"trials":2521,"activeCount":99},[],{"trials":2523,"activeCount":99},[2524],{"nctId":2525,"briefTitle":2526,"status":118,"phases":2527,"primaryCompletion":2528,"completion":2528,"start":2529,"enrollment":2133,"conditions":2530,"interventions":2532},"NCT00479154","Botulinum Toxin to Treat Restless Legs Syndrome",[88,89],"2008-04","2007-05",[2531],"Restless Legs Syndrome",[2516],{"trials":2534,"activeCount":99},[],{"trials":2536,"activeCount":99},[],{"trials":2538,"activeCount":99},[],{"intervention":2540,"totalTrials":112,"cells":2541},"SGS-742",{"EARLY_PHASE1":2542,"PHASE1":2544,"PHASE2":2546,"PHASE3":2559,"PHASE4":2561,"NA":2563},{"trials":2543,"activeCount":99},[],{"trials":2545,"activeCount":99},[],{"trials":2547,"activeCount":99},[2548],{"nctId":2549,"briefTitle":2550,"status":118,"phases":2551,"primaryCompletion":2552,"completion":2553,"start":2554,"enrollment":2555,"conditions":2556,"interventions":2558},"NCT02019667","Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency",[89],"2019-01-31","2019-04-03","2014-03-31",19,[2557,2415],"Metabolic Disease",[2540],{"trials":2560,"activeCount":99},[],{"trials":2562,"activeCount":99},[],{"trials":2564,"activeCount":99},[],{"intervention":2566,"totalTrials":112,"cells":2567},"high-dose intravenous immunoglobulin",{"EARLY_PHASE1":2568,"PHASE1":2570,"PHASE2":2572,"PHASE3":2582,"PHASE4":2584,"NA":2586},{"trials":2569,"activeCount":99},[],{"trials":2571,"activeCount":99},[],{"trials":2573,"activeCount":99},[2574],{"nctId":2575,"briefTitle":2576,"status":118,"phases":2577,"completion":946,"start":2578,"enrollment":1030,"conditions":2579,"interventions":2581},"NCT00034242","High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration",[89],"2002-04",[2580],"Spinocerebellar Degenerations",[2566],{"trials":2583,"activeCount":99},[],{"trials":2585,"activeCount":99},[],{"trials":2587,"activeCount":99},[],{"intervention":1041,"totalTrials":112,"cells":2589},{"EARLY_PHASE1":2590,"PHASE1":2592,"PHASE2":2594,"PHASE3":2600,"PHASE4":2602,"NA":2604},{"trials":2591,"activeCount":99},[],{"trials":2593,"activeCount":99},[],{"trials":2595,"activeCount":99},[2596],{"nctId":1034,"briefTitle":1035,"status":118,"phases":2597,"completion":1037,"start":1038,"enrollment":108,"conditions":2598,"interventions":2599},[89],[28],[1041,1016],{"trials":2601,"activeCount":99},[],{"trials":2603,"activeCount":99},[],{"trials":2605,"activeCount":99},[],{"intervention":2607,"totalTrials":112,"cells":2608},"Botulinum toxin",{"EARLY_PHASE1":2609,"PHASE1":2611,"PHASE2":2613,"PHASE3":2628,"PHASE4":2630,"NA":2632},{"trials":2610,"activeCount":99},[],{"trials":2612,"activeCount":99},[],{"trials":2614,"activeCount":99},[2615],{"nctId":2616,"briefTitle":2617,"status":118,"phases":2618,"primaryCompletion":2619,"completion":2620,"start":2621,"enrollment":108,"conditions":2622,"interventions":2627},"NCT01553201","Botulinum Toxin for Pelvic Pain in Women With Endometriosis",[88,89],"2018-07-31","2019-07-24","2014-07-30",[2623,2624,2625,2626],"Endometriosis","Chronic Pelvic Pain","Pelvic Muscle Spasm","Quality of Life",[2607],{"trials":2629,"activeCount":99},[],{"trials":2631,"activeCount":99},[],{"trials":2633,"activeCount":99},[],{"intervention":2635,"totalTrials":112,"cells":2636},"Recombinant human interferon beta-1a",{"EARLY_PHASE1":2637,"PHASE1":2639,"PHASE2":2641,"PHASE3":2652,"PHASE4":2654,"NA":2656},{"trials":2638,"activeCount":99},[],{"trials":2640,"activeCount":99},[],{"trials":2642,"activeCount":99},[2643],{"nctId":2644,"briefTitle":2645,"status":118,"phases":2646,"completion":1181,"start":832,"enrollment":1089,"conditions":2647,"interventions":2651},"NCT00001785","Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)",[89],[2648,2649,2650],"HTLV-I Infection","Spinal Cord Disease","Tropical Spastic Paraparesis",[2635],{"trials":2653,"activeCount":99},[],{"trials":2655,"activeCount":99},[],{"trials":2657,"activeCount":99},[],{"intervention":2659,"totalTrials":112,"cells":2660},"CEREDASE™",{"EARLY_PHASE1":2661,"PHASE1":2663,"PHASE2":2665,"PHASE3":2676,"PHASE4":2678,"NA":2680},{"trials":2662,"activeCount":99},[],{"trials":2664,"activeCount":99},[],{"trials":2666,"activeCount":99},[2667],{"nctId":2668,"briefTitle":2669,"status":118,"phases":2670,"completion":2671,"start":2672,"enrollment":1222,"conditions":2673,"interventions":2675},"NCT00001416","Bone Response to Enzyme Replacement in Gaucher's Disease",[89],"2000-11","1993-12",[2674],"Gaucher's Disease",[2659],{"trials":2677,"activeCount":99},[],{"trials":2679,"activeCount":99},[],{"trials":2681,"activeCount":99},[],{"intervention":2683,"totalTrials":112,"cells":2684},"DRX005B",{"EARLY_PHASE1":2685,"PHASE1":2687,"PHASE2":2689,"PHASE3":2699,"PHASE4":2701,"NA":2703},{"trials":2686,"activeCount":99},[],{"trials":2688,"activeCount":99},[],{"trials":2690,"activeCount":99},[2691],{"nctId":2692,"briefTitle":2693,"status":118,"phases":2694,"completion":2695,"start":2696,"enrollment":518,"conditions":2697,"interventions":2698},"NCT00048906","Alpha-Galactosidase A Replacement Therapy for Fabry Disease",[89],"2003-11","2002-11",[520],[2683],{"trials":2700,"activeCount":99},[],{"trials":2702,"activeCount":99},[],{"trials":2704,"activeCount":99},[],{"intervention":2706,"totalTrials":112,"cells":2707},"Abciximab",{"EARLY_PHASE1":2708,"PHASE1":2710,"PHASE2":2712,"PHASE3":2722,"PHASE4":2724,"NA":2726},{"trials":2709,"activeCount":99},[],{"trials":2711,"activeCount":99},[],{"trials":2713,"activeCount":99},[2714],{"nctId":2715,"briefTitle":2716,"status":118,"phases":2717,"primaryCompletion":2718,"completion":2719,"start":1711,"enrollment":1098,"conditions":2720,"interventions":2721},"NCT00039832","ReoPro and Retavase to Restore Brain Blood Flow After Stroke",[89],"2007-04","2008-05",[31],[2706],{"trials":2723,"activeCount":99},[],{"trials":2725,"activeCount":99},[],{"trials":2727,"activeCount":99},[],{"intervention":1060,"totalTrials":112,"cells":2729},{"EARLY_PHASE1":2730,"PHASE1":2732,"PHASE2":2734,"PHASE3":2740,"PHASE4":2742,"NA":2744},{"trials":2731,"activeCount":99},[],{"trials":2733,"activeCount":99},[],{"trials":2735,"activeCount":99},[2736],{"nctId":1052,"briefTitle":1053,"status":118,"phases":2737,"completion":1055,"start":1056,"enrollment":1057,"conditions":2738,"interventions":2739},[89],[28],[1060,1016],{"trials":2741,"activeCount":99},[],{"trials":2743,"activeCount":99},[],{"trials":2745,"activeCount":99},[],{"intervention":2747,"totalTrials":112,"cells":2748},"N-0923",{"EARLY_PHASE1":2749,"PHASE1":2751,"PHASE2":2753,"PHASE3":2762,"PHASE4":2764,"NA":2766},{"trials":2750,"activeCount":99},[],{"trials":2752,"activeCount":99},[],{"trials":2754,"activeCount":99},[2755],{"nctId":2756,"briefTitle":2757,"status":118,"phases":2758,"completion":1038,"start":2759,"enrollment":1030,"conditions":2760,"interventions":2761},"NCT00001931","Treatment of Parkinson's Disease With a Transdermal Skin Patch",[89],"1999-05",[17],[2747],{"trials":2763,"activeCount":99},[],{"trials":2765,"activeCount":99},[],{"trials":2767,"activeCount":99},[],{"intervention":1069,"totalTrials":112,"cells":2769},{"EARLY_PHASE1":2770,"PHASE1":2772,"PHASE2":2774,"PHASE3":2780,"PHASE4":2782,"NA":2784},{"trials":2771,"activeCount":99},[],{"trials":2773,"activeCount":99},[],{"trials":2775,"activeCount":99},[2776],{"nctId":1062,"briefTitle":1063,"status":118,"phases":2777,"completion":1065,"start":1066,"enrollment":108,"conditions":2778,"interventions":2779},[89],[17],[1069,1016,1070],{"trials":2781,"activeCount":99},[],{"trials":2783,"activeCount":99},[],{"trials":2785,"activeCount":99},[],{"intervention":1070,"totalTrials":112,"cells":2787},{"EARLY_PHASE1":2788,"PHASE1":2790,"PHASE2":2792,"PHASE3":2798,"PHASE4":2800,"NA":2802},{"trials":2789,"activeCount":99},[],{"trials":2791,"activeCount":99},[],{"trials":2793,"activeCount":99},[2794],{"nctId":1062,"briefTitle":1063,"status":118,"phases":2795,"completion":1065,"start":1066,"enrollment":108,"conditions":2796,"interventions":2797},[89],[17],[1069,1016,1070],{"trials":2799,"activeCount":99},[],{"trials":2801,"activeCount":99},[],{"trials":2803,"activeCount":99},[],{"intervention":2805,"totalTrials":95,"cells":2806},"Muscimol",{"EARLY_PHASE1":2807,"PHASE1":2809,"PHASE2":2827,"PHASE3":2829,"PHASE4":2831,"NA":2833},{"trials":2808,"activeCount":99},[],{"trials":2810,"activeCount":99},[2811,2819],{"nctId":2812,"briefTitle":2813,"status":581,"phases":2814,"completion":2815,"start":2816,"enrollment":518,"conditions":2817,"interventions":2818},"NCT00005925","Brain Infusion of Muscimol to Treat Epilepsy",[88],"2014-12-24","2000-06-23",[20],[2805],{"nctId":2820,"briefTitle":2821,"status":1352,"phases":2822,"completion":2823,"start":2824,"enrollment":99,"conditions":2825,"interventions":2826},"NCT00921128","Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Disease",[88],"2016-09-01","2009-06-02",[28],[2805],{"trials":2828,"activeCount":99},[],{"trials":2830,"activeCount":99},[],{"trials":2832,"activeCount":99},[],{"trials":2834,"activeCount":99},[],{"intervention":2836,"totalTrials":112,"cells":2837},"Sertraline",{"EARLY_PHASE1":2838,"PHASE1":2840,"PHASE2":2850,"PHASE3":2852,"PHASE4":2854,"NA":2856},{"trials":2839,"activeCount":99},[],{"trials":2841,"activeCount":99},[2842],{"nctId":2843,"briefTitle":2844,"status":118,"phases":2845,"completion":2846,"start":2847,"enrollment":108,"conditions":2848,"interventions":2849},"NCT00001777","Sertraline for the Treatment of Patients With Frontal Lobe Dementia (FLD)",[88],"2000-05","1997-12",[1805],[2836],{"trials":2851,"activeCount":99},[],{"trials":2853,"activeCount":99},[],{"trials":2855,"activeCount":99},[],{"trials":2857,"activeCount":99},[],{"intervention":522,"totalTrials":112,"cells":2859},{"EARLY_PHASE1":2860,"PHASE1":2862,"PHASE2":2868,"PHASE3":2870,"PHASE4":2872,"NA":2874},{"trials":2861,"activeCount":99},[],{"trials":2863,"activeCount":99},[2864],{"nctId":513,"briefTitle":514,"status":118,"phases":2865,"primaryCompletion":516,"start":517,"enrollment":518,"conditions":2866,"interventions":2867},[88],[520],[522,505],{"trials":2869,"activeCount":99},[],{"trials":2871,"activeCount":99},[],{"trials":2873,"activeCount":99},[],{"trials":2875,"activeCount":99},[],{"intervention":2877,"totalTrials":112,"cells":2878},"Hu MiK-Beta-1",{"EARLY_PHASE1":2879,"PHASE1":2881,"PHASE2":2893,"PHASE3":2895,"PHASE4":2897,"NA":2899},{"trials":2880,"activeCount":99},[],{"trials":2882,"activeCount":99},[2883],{"nctId":2884,"briefTitle":2885,"status":118,"phases":2886,"primaryCompletion":2887,"completion":2888,"start":2889,"enrollment":2412,"conditions":2890,"interventions":2892},"NCT00076843","Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy\u002FTropical Spastic Paraparesis",[88],"2017-10-11","2019-06-25","2004-02-03",[2891],"HTLV-1",[2877],{"trials":2894,"activeCount":99},[],{"trials":2896,"activeCount":99},[],{"trials":2898,"activeCount":99},[],{"trials":2900,"activeCount":99},[],{"intervention":2902,"totalTrials":112,"cells":2903},"Pembrolizumab",{"EARLY_PHASE1":2904,"PHASE1":2906,"PHASE2":2916,"PHASE3":2918,"PHASE4":2920,"NA":2922},{"trials":2905,"activeCount":99},[],{"trials":2907,"activeCount":99},[2908],{"nctId":2909,"briefTitle":2910,"status":118,"phases":2911,"primaryCompletion":2912,"completion":2912,"start":2913,"enrollment":1688,"conditions":2914,"interventions":2915},"NCT03239899","PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection",[88],"2023-02-13","2018-04-09",[1377],[2902],{"trials":2917,"activeCount":99},[],{"trials":2919,"activeCount":99},[],{"trials":2921,"activeCount":99},[],{"trials":2923,"activeCount":99},[],{"intervention":2925,"totalTrials":112,"cells":2926},"scAAv9\u002FJeT-GAN",{"EARLY_PHASE1":2927,"PHASE1":2929,"PHASE2":2941,"PHASE3":2943,"PHASE4":2945,"NA":2947},{"trials":2928,"activeCount":99},[],{"trials":2930,"activeCount":99},[2931],{"nctId":2932,"briefTitle":2933,"status":118,"phases":2934,"primaryCompletion":2935,"completion":2935,"start":2936,"enrollment":1108,"conditions":2937,"interventions":2940},"NCT02362438","Intrathecal Administration of scAAV9\u002FJeT-GAN for the Treatment of Giant Axonal Neuropathy",[88],"2026-04-10","2015-04-24",[2938,2939],"Giant Axonal Neuropathy","Gene Transfer",[2925],{"trials":2942,"activeCount":99},[],{"trials":2944,"activeCount":99},[],{"trials":2946,"activeCount":99},[],{"trials":2948,"activeCount":99},[],{"intervention":2950,"totalTrials":112,"cells":2951},"Intransal instillation of E-selectin",{"EARLY_PHASE1":2952,"PHASE1":2954,"PHASE2":2966,"PHASE3":2968,"PHASE4":2970,"NA":2972},{"trials":2953,"activeCount":99},[],{"trials":2955,"activeCount":99},[2956],{"nctId":2957,"briefTitle":2958,"status":1352,"phases":2959,"primaryCompletion":2960,"completion":2960,"start":2961,"enrollment":99,"conditions":2962,"interventions":2965},"NCT00069069","E-Selectin Nasal Instillation to Prevent Secondary Stroke",[88],"2018-05-09","2003-10-01",[2963,2964],"Ischemic Attack, Transient","Transient",[2950],{"trials":2967,"activeCount":99},[],{"trials":2969,"activeCount":99},[],{"trials":2971,"activeCount":99},[],{"trials":2973,"activeCount":99},[],{"intervention":2975,"totalTrials":112,"cells":2976},"Guanabenz",{"EARLY_PHASE1":2977,"PHASE1":2979,"PHASE2":2989,"PHASE3":2991,"PHASE4":2993,"NA":2995},{"trials":2978,"activeCount":99},[],{"trials":2980,"activeCount":99},[2981],{"nctId":2982,"briefTitle":2983,"status":581,"phases":2984,"primaryCompletion":2985,"completion":2985,"start":2986,"enrollment":95,"conditions":2987,"interventions":2988},"NCT02423083","Oral Guanabenz for Multiple Sclerosis",[88],"2017-10-30","2015-04-21",[1472,26],[2975],{"trials":2990,"activeCount":99},[],{"trials":2992,"activeCount":99},[],{"trials":2994,"activeCount":99},[],{"trials":2996,"activeCount":99},[],{"intervention":2998,"totalTrials":112,"cells":2999},"IL13-PE38QQR",{"EARLY_PHASE1":3000,"PHASE1":3002,"PHASE2":3013,"PHASE3":3015,"PHASE4":3017,"NA":3019},{"trials":3001,"activeCount":99},[],{"trials":3003,"activeCount":99},[3004],{"nctId":3005,"briefTitle":3006,"status":581,"phases":3007,"primaryCompletion":3008,"completion":3008,"start":3009,"enrollment":1343,"conditions":3010,"interventions":3012},"NCT00880061","An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma",[88],"2015-06-05","2009-04-07",[3011,197],"Brain Neoplasm",[2998],{"trials":3014,"activeCount":99},[],{"trials":3016,"activeCount":99},[],{"trials":3018,"activeCount":99},[],{"trials":3020,"activeCount":99},[],{"intervention":3022,"totalTrials":112,"cells":3023},"IVIg",{"EARLY_PHASE1":3024,"PHASE1":3026,"PHASE2":3038,"PHASE3":3040,"PHASE4":3042,"NA":3044},{"trials":3025,"activeCount":99},[],{"trials":3027,"activeCount":99},[3028],{"nctId":3029,"briefTitle":3030,"status":118,"phases":3031,"completion":3032,"start":3033,"enrollment":1030,"conditions":3034,"interventions":3037},"NCT00001550","Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)",[88],"2002-05","1996-04",[3035,2234,3036],"Muscle Rigidity","Stiff Man Syndrome",[3022],{"trials":3039,"activeCount":99},[],{"trials":3041,"activeCount":99},[],{"trials":3043,"activeCount":99},[],{"trials":3045,"activeCount":99},[],{"intervention":3047,"totalTrials":112,"cells":3048},"Ferumoxytol",{"EARLY_PHASE1":3049,"PHASE1":3051,"PHASE2":3062,"PHASE3":3064,"PHASE4":3066,"NA":3068},{"trials":3050,"activeCount":99},[],{"trials":3052,"activeCount":99},[3053],{"nctId":3054,"briefTitle":3055,"status":118,"phases":3056,"primaryCompletion":3057,"completion":3058,"start":3059,"enrollment":1108,"conditions":3060,"interventions":3061},"NCT02511028","In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging",[88],"2018-08-01","2019-01-29","2015-11-27",[26],[3047],{"trials":3063,"activeCount":99},[],{"trials":3065,"activeCount":99},[],{"trials":3067,"activeCount":99},[],{"trials":3069,"activeCount":99},[],{"intervention":3071,"totalTrials":112,"cells":3072},"Darunavir",{"EARLY_PHASE1":3073,"PHASE1":3075,"PHASE2":3090,"PHASE3":3092,"PHASE4":3094,"NA":3096},{"trials":3074,"activeCount":99},[],{"trials":3076,"activeCount":99},[3077],{"nctId":3078,"briefTitle":3079,"status":118,"phases":3080,"primaryCompletion":3081,"completion":3082,"start":3083,"enrollment":3084,"conditions":3085,"interventions":3086},"NCT02437110","HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)",[88],"2022-11-17","2023-05-09","2019-04-01",122,[335],[3071,3087,3088,3089],"Ritonavir","Dolutegravir","Tenofovir alafenamide",{"trials":3091,"activeCount":99},[],{"trials":3093,"activeCount":99},[],{"trials":3095,"activeCount":99},[],{"trials":3097,"activeCount":99},[],{"intervention":3087,"totalTrials":112,"cells":3099},{"EARLY_PHASE1":3100,"PHASE1":3102,"PHASE2":3108,"PHASE3":3110,"PHASE4":3112,"NA":3114},{"trials":3101,"activeCount":99},[],{"trials":3103,"activeCount":99},[3104],{"nctId":3078,"briefTitle":3079,"status":118,"phases":3105,"primaryCompletion":3081,"completion":3082,"start":3083,"enrollment":3084,"conditions":3106,"interventions":3107},[88],[335],[3071,3087,3088,3089],{"trials":3109,"activeCount":99},[],{"trials":3111,"activeCount":99},[],{"trials":3113,"activeCount":99},[],{"trials":3115,"activeCount":99},[],{"intervention":3088,"totalTrials":112,"cells":3117},{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3126,"PHASE3":3128,"PHASE4":3130,"NA":3132},{"trials":3119,"activeCount":99},[],{"trials":3121,"activeCount":99},[3122],{"nctId":3078,"briefTitle":3079,"status":118,"phases":3123,"primaryCompletion":3081,"completion":3082,"start":3083,"enrollment":3084,"conditions":3124,"interventions":3125},[88],[335],[3071,3087,3088,3089],{"trials":3127,"activeCount":99},[],{"trials":3129,"activeCount":99},[],{"trials":3131,"activeCount":99},[],{"trials":3133,"activeCount":99},[],{"intervention":3089,"totalTrials":112,"cells":3135},{"EARLY_PHASE1":3136,"PHASE1":3138,"PHASE2":3144,"PHASE3":3146,"PHASE4":3148,"NA":3150},{"trials":3137,"activeCount":99},[],{"trials":3139,"activeCount":99},[3140],{"nctId":3078,"briefTitle":3079,"status":118,"phases":3141,"primaryCompletion":3081,"completion":3082,"start":3083,"enrollment":3084,"conditions":3142,"interventions":3143},[88],[335],[3071,3087,3088,3089],{"trials":3145,"activeCount":99},[],{"trials":3147,"activeCount":99},[],{"trials":3149,"activeCount":99},[],{"trials":3151,"activeCount":99},[],{"intervention":3153,"totalTrials":112,"cells":3154},"human glucocerebrosidase cDNA",{"EARLY_PHASE1":3155,"PHASE1":3157,"PHASE2":3166,"PHASE3":3168,"PHASE4":3170,"NA":3172},{"trials":3156,"activeCount":99},[],{"trials":3158,"activeCount":99},[3159],{"nctId":3160,"briefTitle":3161,"status":118,"phases":3162,"completion":2578,"start":3163,"enrollment":2206,"conditions":3164,"interventions":3165},"NCT00001234","Gene Therapy for Gaucher's and Fabry Disease Using Viruses and Blood-Forming Cells",[88],"1988-01",[2674],[3153],{"trials":3167,"activeCount":99},[],{"trials":3169,"activeCount":99},[],{"trials":3171,"activeCount":99},[],{"trials":3173,"activeCount":99},[],{"intervention":3175,"totalTrials":112,"cells":3176},"Nivolumab",{"EARLY_PHASE1":3177,"PHASE1":3179,"PHASE2":3191,"PHASE3":3193,"PHASE4":3195,"NA":3197},{"trials":3178,"activeCount":99},[],{"trials":3180,"activeCount":99},[3181],{"nctId":3182,"briefTitle":3183,"status":118,"phases":3184,"primaryCompletion":3185,"completion":3186,"start":3187,"enrollment":35,"conditions":3188,"interventions":3189},"NCT03493932","Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade",[88],"2023-04-21","2023-06-27","2018-09-24",[876],[3175,3190],"BMS-986016",{"trials":3192,"activeCount":99},[],{"trials":3194,"activeCount":99},[],{"trials":3196,"activeCount":99},[],{"trials":3198,"activeCount":99},[],{"intervention":3190,"totalTrials":112,"cells":3200},{"EARLY_PHASE1":3201,"PHASE1":3203,"PHASE2":3209,"PHASE3":3211,"PHASE4":3213,"NA":3215},{"trials":3202,"activeCount":99},[],{"trials":3204,"activeCount":99},[3205],{"nctId":3182,"briefTitle":3183,"status":118,"phases":3206,"primaryCompletion":3185,"completion":3186,"start":3187,"enrollment":35,"conditions":3207,"interventions":3208},[88],[876],[3175,3190],{"trials":3210,"activeCount":99},[],{"trials":3212,"activeCount":99},[],{"trials":3214,"activeCount":99},[],{"trials":3216,"activeCount":99},[],{"intervention":3218,"totalTrials":112,"cells":3219},"DAC-HYP",{"EARLY_PHASE1":3220,"PHASE1":3222,"PHASE2":3233,"PHASE3":3235,"PHASE4":3237,"NA":3239},{"trials":3221,"activeCount":99},[],{"trials":3223,"activeCount":99},[3224],{"nctId":3225,"briefTitle":3226,"status":118,"phases":3227,"primaryCompletion":3228,"completion":3228,"start":3229,"enrollment":3230,"conditions":3231,"interventions":3232},"NCT01143441","Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)",[88],"2017-08-11","2010-05-13",48,[26,1472],[3218],{"trials":3234,"activeCount":99},[],{"trials":3236,"activeCount":99},[],{"trials":3238,"activeCount":99},[],{"trials":3240,"activeCount":99},[],{"intervention":3242,"totalTrials":112,"cells":3243},"Lithium Carbonate",{"EARLY_PHASE1":3244,"PHASE1":3246,"PHASE2":3257,"PHASE3":3259,"PHASE4":3261,"NA":3263},{"trials":3245,"activeCount":99},[],{"trials":3247,"activeCount":99},[3248],{"nctId":3249,"briefTitle":3250,"status":118,"phases":3251,"primaryCompletion":3252,"completion":3252,"start":3253,"enrollment":1688,"conditions":3254,"interventions":3256},"NCT00683943","Lithium Treatment for Patients With Spinocerebellar Ataxia Type I",[88],"2010-02-25","2008-05-18",[3255],"Spinocerebellar Ataxia Type I",[3242],{"trials":3258,"activeCount":99},[],{"trials":3260,"activeCount":99},[],{"trials":3262,"activeCount":99},[],{"trials":3264,"activeCount":99},[],{"intervention":3266,"totalTrials":112,"cells":3267},"N-Acetylcysteine",{"EARLY_PHASE1":3268,"PHASE1":3270,"PHASE2":3281,"PHASE3":3283,"PHASE4":3285,"NA":3287},{"trials":3269,"activeCount":99},[],{"trials":3271,"activeCount":99},[3272],{"nctId":3273,"briefTitle":3274,"status":581,"phases":3275,"primaryCompletion":3276,"completion":3276,"start":3277,"enrollment":2133,"conditions":3278,"interventions":3280},"NCT03104725","Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?",[88],"2020-02-27","2017-09-25",[17,3279],"Cerebrospinal Fluid",[3266],{"trials":3282,"activeCount":99},[],{"trials":3284,"activeCount":99},[],{"trials":3286,"activeCount":99},[],{"trials":3288,"activeCount":99},[],{"intervention":3290,"totalTrials":112,"cells":3291},"Interferon beta-1a",{"EARLY_PHASE1":3292,"PHASE1":3294,"PHASE2":3304,"PHASE3":3306,"PHASE4":3308,"NA":3310},{"trials":3293,"activeCount":99},[],{"trials":3295,"activeCount":99},[3296],{"nctId":3297,"briefTitle":3298,"status":118,"phases":3299,"completion":3300,"start":3301,"enrollment":1915,"conditions":3302,"interventions":3303},"NCT00097318","Safety Study of Interferon Beta 1a to for Acute Stroke",[88],"2011-04-08","2004-11-17",[31],[3290],{"trials":3305,"activeCount":99},[],{"trials":3307,"activeCount":99},[],{"trials":3309,"activeCount":99},[],{"trials":3311,"activeCount":99},[],{"intervention":3313,"totalTrials":112,"cells":3314},"Convection enhanced delivery\u002FAAV2-GDNF",{"EARLY_PHASE1":3315,"PHASE1":3317,"PHASE2":3327,"PHASE3":3329,"PHASE4":3331,"NA":3333},{"trials":3316,"activeCount":99},[],{"trials":3318,"activeCount":99},[3319],{"nctId":3320,"briefTitle":3321,"status":118,"phases":3322,"primaryCompletion":3323,"completion":3323,"start":3324,"enrollment":32,"conditions":3325,"interventions":3326},"NCT01621581","AAV2-GDNF for Advanced Parkinson s Disease",[88],"2022-02-04","2013-03-13",[28],[3313],{"trials":3328,"activeCount":99},[],{"trials":3330,"activeCount":99},[],{"trials":3332,"activeCount":99},[],{"trials":3334,"activeCount":99},[],{"intervention":3336,"totalTrials":112,"cells":3337},"Sodium Nitrite",{"EARLY_PHASE1":3338,"PHASE1":3340,"PHASE2":3350,"PHASE3":3352,"PHASE4":3354,"NA":3356},{"trials":3339,"activeCount":99},[],{"trials":3341,"activeCount":99},[3342],{"nctId":3343,"briefTitle":3344,"status":118,"phases":3345,"primaryCompletion":3346,"completion":3346,"start":3347,"enrollment":1089,"conditions":3348,"interventions":3349},"NCT00103025","Nitrite Infusion in Healthy Volunteers",[88],"2011-05-10","2005-02-04",[14],[3336,3336],{"trials":3351,"activeCount":99},[],{"trials":3353,"activeCount":99},[],{"trials":3355,"activeCount":99},[],{"trials":3357,"activeCount":99},[],{"intervention":3359,"totalTrials":112,"cells":3360},"[11C] Raclopride",{"EARLY_PHASE1":3361,"PHASE1":3363,"PHASE2":3373,"PHASE3":3375,"PHASE4":3377,"NA":3379},{"trials":3362,"activeCount":99},[],{"trials":3364,"activeCount":99},[3365],{"nctId":3366,"briefTitle":3367,"status":118,"phases":3368,"primaryCompletion":3369,"completion":3369,"start":3370,"enrollment":244,"conditions":3371,"interventions":3372},"NCT02169310","Neural Basis of Decision-Making Deficits in Traumatic Brain Injury",[88],"2024-02-13","2014-11-18",[2184],[3359],{"trials":3374,"activeCount":99},[],{"trials":3376,"activeCount":99},[],{"trials":3378,"activeCount":99},[],{"trials":3380,"activeCount":99},[],{"intervention":3382,"totalTrials":112,"cells":3383},"Cytovene",{"EARLY_PHASE1":3384,"PHASE1":3386,"PHASE2":3397,"PHASE3":3399,"PHASE4":3401,"NA":3403},{"trials":3385,"activeCount":99},[],{"trials":3387,"activeCount":99},[3388],{"nctId":3389,"briefTitle":3390,"status":118,"phases":3391,"primaryCompletion":3392,"completion":3392,"start":3393,"enrollment":354,"conditions":3394,"interventions":3396},"NCT00001328","Gene Therapy for the Treatment of Brain Tumors",[88],"2010-04-30","1992-08-21",[3011,3395],"Neoplasm Metastasis",[3382],{"trials":3398,"activeCount":99},[],{"trials":3400,"activeCount":99},[],{"trials":3402,"activeCount":99},[],{"trials":3404,"activeCount":99},[],{"intervention":3406,"totalTrials":112,"cells":3407},"Gentamicin",{"EARLY_PHASE1":3408,"PHASE1":3410,"PHASE2":3420,"PHASE3":3422,"PHASE4":3424,"NA":3426},{"trials":3409,"activeCount":99},[],{"trials":3411,"activeCount":99},[3412],{"nctId":3413,"briefTitle":3414,"status":118,"phases":3415,"completion":1038,"start":1579,"enrollment":506,"conditions":3416,"interventions":3419},"NCT00005574","Gentamicin Treatment of Muscular Dystrophy",[88],[3417,3418],"Becker Muscular Dystrophy","Duchenne Muscular Dystrophy",[3406],{"trials":3421,"activeCount":99},[],{"trials":3423,"activeCount":99},[],{"trials":3425,"activeCount":99},[],{"trials":3427,"activeCount":99},[],{"intervention":3429,"totalTrials":112,"cells":3430},"Raltegravir",{"EARLY_PHASE1":3431,"PHASE1":3441,"PHASE2":3443,"PHASE3":3445,"PHASE4":3447,"NA":3449},{"trials":3432,"activeCount":99},[3433],{"nctId":3434,"briefTitle":3435,"status":118,"phases":3436,"primaryCompletion":3437,"completion":3437,"start":3438,"enrollment":2555,"conditions":3439,"interventions":3440},"NCT01867320","Raltegravir for HAM\u002FTSP",[87],"2018-09-25","2013-09-05",[2648],[3429],{"trials":3442,"activeCount":99},[],{"trials":3444,"activeCount":99},[],{"trials":3446,"activeCount":99},[],{"trials":3448,"activeCount":99},[],{"trials":3450,"activeCount":99},[],{"intervention":3452,"totalTrials":112,"cells":3453},"PyVST",{"EARLY_PHASE1":3454,"PHASE1":3465,"PHASE2":3467,"PHASE3":3469,"PHASE4":3471,"NA":3473},{"trials":3455,"activeCount":99},[3456],{"nctId":3457,"briefTitle":3458,"status":118,"phases":3459,"primaryCompletion":3460,"completion":3461,"start":3462,"enrollment":1915,"conditions":3463,"interventions":3464},"NCT02694783","Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells",[87],"2019-12-13","2020-03-06","2016-03-28",[224],[3452],{"trials":3466,"activeCount":99},[],{"trials":3468,"activeCount":99},[],{"trials":3470,"activeCount":99},[],{"trials":3472,"activeCount":99},[],{"trials":3474,"activeCount":99},[],{"intervention":3476,"totalTrials":112,"cells":3477},"NT-I7",{"EARLY_PHASE1":3478,"PHASE1":3488,"PHASE2":3490,"PHASE3":3492,"PHASE4":3494,"NA":3496},{"trials":3479,"activeCount":99},[3480],{"nctId":3481,"briefTitle":3482,"status":118,"phases":3483,"primaryCompletion":3484,"completion":3484,"start":3485,"enrollment":1089,"conditions":3486,"interventions":3487},"NCT04781309","NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy",[87],"2025-11-07","2021-05-05",[224],[3476],{"trials":3489,"activeCount":99},[],{"trials":3491,"activeCount":99},[],{"trials":3493,"activeCount":99},[],{"trials":3495,"activeCount":99},[],{"trials":3497,"activeCount":99},[],{"intervention":3499,"totalTrials":112,"cells":3500},"Acthrel",{"EARLY_PHASE1":3501,"PHASE1":3513,"PHASE2":3515,"PHASE3":3517,"PHASE4":3519,"NA":3521},{"trials":3502,"activeCount":99},[3503],{"nctId":3504,"briefTitle":3505,"status":118,"phases":3506,"primaryCompletion":3507,"completion":3508,"start":3509,"enrollment":108,"conditions":3510,"interventions":3512},"NCT01459237","Effects of Hormone Stimulation on Brain Scans for Cushing s Disease",[87],"2018-01-30","2018-06-12","2011-10-11",[3511],"Pituitary Neoplasm",[3499],{"trials":3514,"activeCount":99},[],{"trials":3516,"activeCount":99},[],{"trials":3518,"activeCount":99},[],{"trials":3520,"activeCount":99},[],{"trials":3522,"activeCount":99},[],{"intervention":3524,"totalTrials":95,"cells":3525},"0-15 Water",{"EARLY_PHASE1":3526,"PHASE1":3528,"PHASE2":3530,"PHASE3":3542,"PHASE4":3544,"NA":3546},{"trials":3527,"activeCount":99},[],{"trials":3529,"activeCount":99},[],{"trials":3531,"activeCount":99},[3532],{"nctId":3533,"briefTitle":3534,"status":118,"phases":3535,"completion":3536,"start":3537,"enrollment":3538,"conditions":3539,"interventions":3541},"NCT00001783","Motor Recovery in Recent Stroke Patients Treated With Amphetamine and Physical Therapy",[89],"2004-06","1998-04",34,[31,3540],"Paralysis",[3524],{"trials":3543,"activeCount":99},[],{"trials":3545,"activeCount":99},[],{"trials":3547,"activeCount":99},[3548],{"nctId":3549,"briefTitle":3550,"status":118,"phases":3551,"completion":3552,"start":874,"enrollment":1030,"conditions":3553,"interventions":3554},"NCT00088569","Effect of Direct Current Polarization on Brain Function",[],"2006-06",[14],[3524],{"intervention":3556,"totalTrials":95,"cells":3557},"Estrogen",{"EARLY_PHASE1":3558,"PHASE1":3560,"PHASE2":3562,"PHASE3":3564,"PHASE4":3573,"NA":3575},{"trials":3559,"activeCount":99},[],{"trials":3561,"activeCount":99},[],{"trials":3563,"activeCount":99},[],{"trials":3565,"activeCount":99},[3566],{"nctId":3567,"briefTitle":3568,"status":118,"phases":3569,"start":2672,"conditions":3570,"interventions":3571},"NCT00026039","Women's Estrogen for Stroke Trial (WEST)",[90],[23],[3572],"estrogen",{"trials":3574,"activeCount":99},[],{"trials":3576,"activeCount":99},[3577],{"nctId":3578,"briefTitle":3579,"status":118,"phases":3580,"start":3581,"enrollment":3582,"conditions":3583,"interventions":3584},"NCT00004274","Effect of Estrogen on Mental and Social Functioning in Girls With Turner's Syndrome",[92],"1990-02",260,[1762],[3556],{"intervention":3586,"totalTrials":95,"cells":3587},"15 O Water",{"EARLY_PHASE1":3588,"PHASE1":3590,"PHASE2":3592,"PHASE3":3594,"PHASE4":3596,"NA":3598},{"trials":3589,"activeCount":99},[],{"trials":3591,"activeCount":99},[],{"trials":3593,"activeCount":99},[],{"trials":3595,"activeCount":99},[],{"trials":3597,"activeCount":99},[],{"trials":3599,"activeCount":99},[3600,3611],{"nctId":3601,"briefTitle":3602,"status":118,"phases":3603,"completion":3604,"start":3605,"enrollment":3606,"conditions":3607,"interventions":3609},"NCT00001288","Brain Blood Flow Studies of Language and Memory",[],"2003-06","1991-05",303,[3608,20],"Cerebrovascular Disorder",[3586,3610],"FDG",{"nctId":3612,"briefTitle":3613,"status":118,"phases":3614,"completion":3615,"start":3616,"enrollment":3617,"conditions":3618,"interventions":3620},"NCT00001972","PET Scan of Brain Metabolism in Relation to Age and Disease",[],"2002-08","1994-09",123,[1804,3011,3619],"Niemann Pick Disease",[3586],{"intervention":3622,"totalTrials":112,"cells":3623},"O15",{"EARLY_PHASE1":3624,"PHASE1":3626,"PHASE2":3628,"PHASE3":3630,"PHASE4":3632,"NA":3634},{"trials":3625,"activeCount":99},[],{"trials":3627,"activeCount":99},[],{"trials":3629,"activeCount":99},[],{"trials":3631,"activeCount":99},[],{"trials":3633,"activeCount":99},[],{"trials":3635,"activeCount":99},[3636],{"nctId":3637,"briefTitle":3638,"status":118,"phases":3639,"completion":2695,"start":1892,"enrollment":244,"conditions":3640,"interventions":3643},"NCT00001926","The Connection Between Areas in the Brain of Blind Patients",[],[3641,3642,14],"Blindness","Brain Mapping",[3622],{"intervention":3645,"totalTrials":112,"cells":3646},"18 FDG",{"EARLY_PHASE1":3647,"PHASE1":3649,"PHASE2":3651,"PHASE3":3653,"PHASE4":3655,"NA":3657},{"trials":3648,"activeCount":99},[],{"trials":3650,"activeCount":99},[],{"trials":3652,"activeCount":99},[],{"trials":3654,"activeCount":99},[],{"trials":3656,"activeCount":99},[],{"trials":3658,"activeCount":99},[3659],{"nctId":3660,"briefTitle":3661,"status":118,"phases":3662,"completion":3536,"start":3663,"enrollment":1760,"conditions":3664,"interventions":3667},"NCT00001325","Metabolic Abnormalities in Children With Epilepsy",[],"1992-04",[3665,3666,2557,2343,2415],"Generalized Epilepsy","Infantile Spasms",[3645],{"intervention":3669,"totalTrials":112,"cells":3670},"Raclopride",{"EARLY_PHASE1":3671,"PHASE1":3673,"PHASE2":3675,"PHASE3":3677,"PHASE4":3679,"NA":3681},{"trials":3672,"activeCount":99},[],{"trials":3674,"activeCount":99},[],{"trials":3676,"activeCount":99},[],{"trials":3678,"activeCount":99},[],{"trials":3680,"activeCount":99},[],{"trials":3682,"activeCount":99},[3683],{"nctId":3684,"briefTitle":3685,"status":118,"phases":3686,"completion":1554,"start":1711,"enrollment":3687,"conditions":3688,"interventions":3689},"NCT00032812","The Role of Dopamine in Motor Learning in Healthy Subjects and Patients With Parkinson's Disease",[],64,[17,14],[3669],{"intervention":3691,"totalTrials":112,"cells":3692},"[18F]FP-TZTP",{"EARLY_PHASE1":3693,"PHASE1":3695,"PHASE2":3697,"PHASE3":3699,"PHASE4":3701,"NA":3703},{"trials":3694,"activeCount":99},[],{"trials":3696,"activeCount":99},[],{"trials":3698,"activeCount":99},[],{"trials":3700,"activeCount":99},[],{"trials":3702,"activeCount":99},[],{"trials":3704,"activeCount":99},[3705],{"nctId":3706,"briefTitle":3707,"status":118,"phases":3708,"primaryCompletion":3709,"completion":3709,"start":3710,"enrollment":21,"conditions":3711,"interventions":3714},"NCT02689466","Cholinergic Receptor Imaging in Dystonia",[],"2021-11-26","2016-12-16",[3712,1690,3713,34],"Cervical Dystonia","Movement Disorder",[3691],{"intervention":3610,"totalTrials":112,"cells":3716},{"EARLY_PHASE1":3717,"PHASE1":3719,"PHASE2":3721,"PHASE3":3723,"PHASE4":3725,"NA":3727},{"trials":3718,"activeCount":99},[],{"trials":3720,"activeCount":99},[],{"trials":3722,"activeCount":99},[],{"trials":3724,"activeCount":99},[],{"trials":3726,"activeCount":99},[],{"trials":3728,"activeCount":99},[3729],{"nctId":3601,"briefTitle":3602,"status":118,"phases":3730,"completion":3604,"start":3605,"enrollment":3606,"conditions":3731,"interventions":3732},[],[3608,20],[3586,3610],{"intervention":3734,"totalTrials":112,"cells":3735},"I-123-5-IA85380",{"EARLY_PHASE1":3736,"PHASE1":3738,"PHASE2":3740,"PHASE3":3742,"PHASE4":3744,"NA":3746},{"trials":3737,"activeCount":99},[],{"trials":3739,"activeCount":99},[],{"trials":3741,"activeCount":99},[],{"trials":3743,"activeCount":99},[],{"trials":3745,"activeCount":99},[],{"trials":3747,"activeCount":99},[3748],{"nctId":3749,"briefTitle":3750,"status":118,"phases":3751,"completion":1116,"start":1442,"enrollment":1915,"conditions":3752,"interventions":3753},"NCT00058721","Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease",[],[17],[3734],{"intervention":426,"totalTrials":112,"cells":3755},{"EARLY_PHASE1":3756,"PHASE1":3758,"PHASE2":3760,"PHASE3":3762,"PHASE4":3764,"NA":3766},{"trials":3757,"activeCount":99},[],{"trials":3759,"activeCount":99},[],{"trials":3761,"activeCount":99},[],{"trials":3763,"activeCount":99},[],{"trials":3765,"activeCount":99},[],{"trials":3767,"activeCount":99},[3768],{"nctId":417,"briefTitle":418,"status":118,"phases":3769,"primaryCompletion":420,"completion":420,"start":421,"enrollment":408,"conditions":3770,"interventions":3771},[],[17,423,424],[426,427,80],{"intervention":427,"totalTrials":112,"cells":3773},{"EARLY_PHASE1":3774,"PHASE1":3776,"PHASE2":3778,"PHASE3":3780,"PHASE4":3782,"NA":3784},{"trials":3775,"activeCount":99},[],{"trials":3777,"activeCount":99},[],{"trials":3779,"activeCount":99},[],{"trials":3781,"activeCount":99},[],{"trials":3783,"activeCount":99},[],{"trials":3785,"activeCount":99},[3786],{"nctId":417,"briefTitle":418,"status":118,"phases":3787,"primaryCompletion":420,"completion":420,"start":421,"enrollment":408,"conditions":3788,"interventions":3789},[],[17,423,424],[426,427,80]]